Health Promotion and Human Behavior : Kyoto University / 京都大学大学院 医学研究科 社会健康医学系専攻 健康増進・行動学分野

Publications

Recent publications

2023-

  1. Funada S, Luo Y, Uozumi R, Watanabe N, Goto T, Negoro H, Ueno K, Ichioka K, Segawa T, Akechi T, Ogawa O, Akamatsu S, Kobayashi T & Furukawa TA (2024) Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. JAMA Network Open, 7, e241784. https://doi.org/10.1001/jamanetworkopen.2024.1784 
  2. Akechi T, Furukawa TA, Noma H, Iwata H, Toyama T, Higaki K, Matsuoka H, Zenda S, Iwatani T, Akahane K, Inoue A, Sagara Y, Uchida M, Imai F, Momino K, Imaizumi G, Yamaguchi T, Mashiko T, Miyaji T, Horikoshi M, Sakurai N, Onishi T, Kanemitsu Y, Murata T, Wanifuchi-Endo Y, Kuroda H, Nishikawa R, Miyashita M, Abe M, Uchitomi Y & J-SUPPORT 2001 Study (2024) Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study). Psychiatry and Clinical Neurosciences, n/a. https://doi.org/https://doi.org/10.1111/pcn.13657  
  3. Levine SZ, Goldberg Y, Rotstein A, Samara M, Yoshida K, Cipriani A, Iwatsubo T, Leucht S & Furukawa TA (in press) Shortening the Alzheimer's Disease Assessment Scale Cognitive Subscale: Individual participant aata from five double-blind randomized, placebo-controlled, clinical trials of donepezil. European Psychiatry
  4. Leucht S, Siafis S, Schneider-Thoma J, Tajika A, Priller J, Davis JM & Furukawa TA (in press) Are the results of open randomised controlled trials comparing antipsychotic drugs in schizophrenia biased? Exploratory meta- and subgroup analysis. Schizophrenia
  5. Heimke F, Furukawa Y, Siafis S, Johnston BC, Engel RR, Furukawa TA & Leucht S (2024) Understanding effect size: an international online survey among psychiatrists, psychologists, physicians from other medical specialities, dentists and other health professionals. BMJ Mental Health, 27. https://doi.org/10.1136/bmjment-2023-300978
  6. Furukawa Y, Sakata M, Yamamoto R, Nakajima S, Kikuchi S, Inoue M, Ito M, Noma H, Takashina HN, Funada S, Ostinelli EG, Furukawa TA, Efthimiou O & Perlis M (2024) Components and Delivery Formats of Cognitive Behavioral Therapy for Chronic Insomnia in Adults: A Systematic Review and Component Network Meta-Analysis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2023.5060 
  7.  So R, Emura N, Okazaki K, Takeda S, Sunami T, Kitagawa K, Takebayashi Y & Furukawa TA (in press) Guided versus unguided chatbot-delivered cognitive behavioral intervention for individuals with moderate-risk and problem gambling: A randomized controlled trial (GAMBOT2 study). Addictive Behaviors, 149, 107889. https://doi.org/10.1016/j.addbeh.2023.107889 
  8. Deisenhofer AK, Barkham M, Beierl ET, Schwartz B, Aafjes-van Doorn K, Beevers CG, Berwian IM, Blackwell SE, Bockting CL, Brakemeier EL, Brown G, Buckman JEJ, Castonguay LG, Cusack CE, Dalgleish T, de Jong K, Delgadillo J, DeRubeis RJ, Driessen E, Ehrenreich-May J, Fisher AJ, Fried EI, Fritz J, Furukawa TA, Gillan CM, Gomez Penedo JM, Hitchcock PF, Hofmann SG, Hollon SD, Jacobson NC, Karlin DR, Lee CT, Levinson CA, Lorenzo-Luaces L, McDanal R, Moggia D, Ng MY, Norris LA, Patel V, Piccirillo ML, Pilling S, Rubel JA, Salazar-de-Pablo G, Schleider JL, Schnurr PP, Schueller SM, Siegle GJ, Uher R, Watkins E, Webb CA, Wiltsey Stirman S, Wynants L, Youn SJ, Zilcha-Mano S, Lutz W & Cohen ZD (in press) Implementing precision methods in personalizing psychological therapies: Barriers and possible ways forward. Behaviour Research and Therapy, 172, 104443. https://doi.org/10.1016/j.brat.2023.104443 
  9. Benrimoh D, Kleinerman A, Furukawa TA, Reynolds III CF, Lenze EJ, Karp J, Mulsant B, Armstrong C, Mehltretter J, Fratila R, Perlman K, Israel S, Popescu C, Golden G, Qassim S, Anacleto A, Tanguay-Sela M, Kapelner A, Rosenfeld A & Turecki G (in press) Towards outcome-driven patient subgroups: A machine learning analysis across six depression treatment studies American Journal of Geriatric Psychiatry
  10. Cuijpers P, Miguel C, Ciharova M, Harrer M, Basic D, Cristea IA, de Ponti N, Driessen E, Hamblen J, Larsen SE, Matbouriahi M, Papola D, Pauley D, Plessen CY, Pfund RA, Setkowski K, Schnurr PP, van Ballegooijen W, Wang Y, Riper H, van Straten A, Sijbrandij M, Furukawa TA & Karyotaki E (in press) Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. World Psychiatry
  11. Domschke K, Seuling PD, Schiele MA, Bandelow B, Batelaan NM, Bokma WA, Branchi I, Burkauskas J, Davies SJC, Dell'Osso B, Fagan H, Fineberg NA, Furukawa TA, Hofmann SG, Hood SD, Huneke NTM, Latas M, Lidbetter N, Masdrakis V, McAllister-Williams RH, Nardi AE, Pallanti S, Penninx BW, Perna G, Pilling S, Pini S, Reif A, Seedat S, Simons G, Srivastava S, Steibliene V, Stein DJ, Stein M, van Ameringen M, van Balkom AJ, van der Wee N, Zwanger P & Baldwin DS (in press) The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline. World Psychiatry
  12. Hosozawa M, Ando S, Yamaguchi S, Yamasaki S, DeVylder J, Miyashita M, Endo K, Stanyon D, Knowles G, Nakanishi M, Usami S, Iso H, Furukawa TA, Hiraiwa-Hasegawa M, Kasai K & Nishida A (in press) Sex difference in adolescent depression trajectory before and into the second year of COVID-19 pandemic. Journal of the American Academy of Child and Adolescent Psychiatry
  13. Sahker E, Furukawa TA, Luo Y, Ferreira ML, Okazaki K, Chevance A, Markham S, Ede R, Leucht S, Cipriani A & Salanti G (2024) Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. BMJ Mental Health, 27. https://doi.org/10.1136/bmjment-2023-300919
  14. Sakurai H, Noma H, Watanabe K, Uchida H & Furukawa TA (2024) Cumulative remission rate after sequential treatments in depression: reappraisal of the STAR*D trial data. World Psychiatry, 23, 156-157. https://doi.org/10.1002/wps.21169
  15. So R, Sato Y, Hashimoto N & Furukawa TA (in press) Prevalence of suspected autism spectrum disorder and attention-deficit hyperactivity disorder in a Japanese clinical sample with gambling disorder: A cross-sectional study. Psychiatry and Clinical Neurosciences Reports
  16. Veal C, Tomlinson A, Cipriani A, Bulteau S, Henry C, Müh C, Touboul S, De Waal N, Levy-Soussan H, Furukawa TA, Fried EI, Tran V-T & Chevance A (2024) Heterogeneity of outcome measures in depression trials and the relevance of the content of outcome measures to patients: a systematic review. Lancet Psychiatry, 11, 285-294. https://doi.org/10.1016/s2215-0366(23)00438-8  
  17. Yasukawa S, Tanaka T, Yamane K, Kano R, Sakata M, Noma H, Furukawa TA & Kishimoto T (2024) A chatbot to improve adherence to internet-based cognitive-behavioural therapy among workers with subthreshold depression: a randomised controlled trial. BMJ Mental Health, 27. https://doi.org/10.1136/bmjment-2023-300881
  18.  Akechi T, Yamaguchi T, Uchida M, Imai F, Momino K, Katsuki F, Sakurai N, Miyaji T, Mashiko T, Horikoshi M, Furukawa TA, Yoshimura A, Ohno S, Uehiro N, Higaki K, Hasegawa Y, Akahane K, Uchitomi Y & Iwata H (2023) Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study). Journal of Clinical Oncology, 41, 1069-1078. https://doi.org/10.1200/JCO.22.00699 
  19. Bossarte RM, Ross EL, Liu H, Turner B, Bryant C, Zainal NH, Puac-Polanco V, Ziobrowski HN, Cui R, Cipriani A, Furukawa TA, Leung LB, Joormann J, Nierenberg AA, Oslin DW, Pigeon WR, Post EP, Zaslavsky AM, Zubizarreta JR, Luedtke A, Kennedy CJ & Kessler RC (2023) Development of a model to predict combined antidepressant medication and psychotherapy treatment response for depression among veterans. Journal of Affective Disorders, 326, 111-119. https://doi.org/10.1016/j.jad.2023.01.082 
  20. Bouchi R, Noda M, Hayashino Y, Goto A, Yamazaki K, Suzuki H, Furukawa TA, Izumi K & Kobayashi M (2023) Behavioral change stage might moderate the impact of multifaceted interventions on non-attendance from medical care among patients with type 2 diabetes: The Japan Diabetes Outcome Intervention Trial-2 Large-Scale Trial 007 (J-DOIT2-LT007). J Diabetes Investig, 14, 907-916. https://doi.org/10.1111/jdi.14012 
  21. Chiocchia V, Furukawa TA, Schneider-Thoma J, Siafis S, Cipriani A, Leucht S & Salanti G (2023) Estimating and visualising the trade-off between benefits and harms on multiple clinical outcomes in network meta-analysis. Systematic Reviews, 12, 209. https://doi.org/10.1186/s13643-023-02376-1 
  22. Cipriani A, Seedat S, Milligan L, Salanti G, Macleod M, Hastings J, Thomas J, Michie S, Furukawa TA, Gilbert D, Soares-Weiser K, Moreno C, Leucht S, Egger M, Mansoori P, Barker JM, Siafis S, Ostinelli EG, McCutcheon R, Wright S, Simpson M, Elugbadebo O, Chiocchia V, Tonia T, Elgarf R, Kurtulmus A, Sena E, Simple O, Boyce N, Chung S, Sharma A, Wolpert M, Potts J & Elliott JH (2023) New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis. BMJ Mental Health, 26. https://doi.org/10.1136/bmjment-2023-300759 
  23. Cipriani A, Seedat S, Milligan L, Salanti G, Macleod M, Hastings J, Thomas J, Michie S, Furukawa TA, Gilbert D, Soares-Weiser K, Moreno C, Leucht S, Egger M, Mansoori P, Barker JM, Siafis S, Ostinelli EG, McCutcheon R, Wright S, Simpson M, Elugbadebo O, Chiocchia V, Tonia T, Elgarf R, Kurtulmus A, Sena E, Simple O, Boyce N, Chung S, Sharma A, Wolpert M, Potts J & Elliott JH (2023) New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis. BMJ Mental Health, 26. https://doi.org/10.1136/bmjment-2023-300759 
  24. Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H, Stikkelbroek Y, Weisz JR & Furukawa TA (2023) The effects of psychological treatments of depression in children and adolescents on response, reliable change, and deterioration: a systematic review and meta-analysis. European Child and Adolescent Psychiatry, 32, 177-192. https://doi.org/10.1007/s00787-021-01884-6 
  25. Efthimiou O, Hoogland J, Debray TPA, Seo M, Furukawa TA, Egger M & White IR (2023) Measuring the performance of prediction models to personalize treatment choice. Statistics in Medicine, 42, 1188-1206. https://doi.org/10.1002/sim.9665 
  26. Farhat LC, Flores JM, Avila-Quintero VJ, Polanczyk GV, Cipriani A, Furukawa TA, Bloch MH & Cortese S (2023) Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2023.3985 
  27. Funada S, Yoshioka T, Luo Y, Iwama T, Mori C, Yamada N, Yoshida H, Katanoda K & Furukawa TA (2023) Global Trends in Highly Cited Studies in COVID-19 Research. JAMA Network Open, 6, e2332802. https://doi.org/10.1001/jamanetworkopen.2023.32802 
  28. Funada S, Luo Y, Kataoka Y, Yoshioka T, Fujita Y, Yoshida S, Katsura M, Tada M, Nishioka N, Nakamura Y, Ueno K, Uozumi R & Furukawa TA (2023) Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study. BMJ Evidence-Based Medicine, 28, 372-382. https://doi.org/10.1136/bmjebm-2023-112332 
  29. Furukawa TA (2023) Complexities of treatment-resistant depression: cautionary notes and promising avenues. World Psychiatry, 22, 419-420. https://doi.org/10.1002/wps.21139 
  30. Furukawa TA, Iwata S, Horikoshi M, Sakata M, Toyomoto R, Luo Y, Tajika A, Kudo N & Aramaki E (2023) Harnessing AI to Optimize Thought Records and Facilitate Cognitive Restructuring in Smartphone CBT: An Exploratory Study. Cognitive Therapy and Research, 47, 887-893. https://doi.org/10.1007/s10608-023-10411-7 
  31. Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, Furukawa TA & Kataoka Y (2023) Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open, 13, e061023. https://doi.org/10.1136/bmjopen-2022-061023 
  32. Furukawa TA, Tajika A, Sakata M, Luo Y, Toyomoto R, Horikoshi M, Akechi T, Kawakami N, Nakayama T, Kondo N, Fukuma S, Noma H, Christensen H, Kessler RC, Cuijpers P & Wason JMS (2023) Four 2x2 factorial trials of smartphone CBT to reduce subthreshold depression and to prevent new depressive episodes among adults in the community-RESiLIENT trial (Resilience Enhancement with Smartphone in LIving ENvironmenTs): a master protocol. BMJ Open, 13, e067850. https://doi.org/10.1136/bmjopen-2022-067850 
  33. Guaiana G, Meader N, Barbui C, Davies SJ, Furukawa TA, Imai H, Dias S, Caldwell DM, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A, Dawson S & Robertson L (2023) Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 11, CD012729. https://doi.org/10.1002/14651858.CD012729.pub3 
  34. Hamza T, Chalkou K, Pellegrini F, Kuhle J, Benkert P, Lorscheider J, Zecca C, Iglesias-Urrutia CP, Manca A, Furukawa TA, Cipriani A & Salanti G (2023) Synthesizing cross-design evidence and cross-format data using network meta-regression. Research Synthesis Methods, 14, 283-300. https://doi.org/10.1002/jrsm.1619 
  35. Hwang C, Takano T, So R, Sahker E, Kawakami S, Livingstone C, Takiguchi N, Ono-Kihara M, Kihara M & Furukawa TA (2023) Prevalence of gambling disorder and its correlates among homeless men in Osaka city, Japan. Journal of Gambling Studies, 39, 1059-1076. https://doi.org/10.1007/s10899-022-10121-x 
  36. Inaba S, Yamamoto K, Kaga T, Wannous M, Sakata M, Yamaguchi O & Furukawa TA (2023) Protocol for development of an assessment tool for competency of ECG interpretation: expert consensus by the RAND/UCLA appropriateness method and cross-sectional testing using multidimensional item response theory. BMJ Open, 13, e072097. https://doi.org/10.1136/bmjopen-2023-072097 
  37. Inayama Y, Takamatsu S, Hamanishi J, Mizuno K, Horinouchi N, Yamanoi K, Taki M, Murakami R, Yamaguchi K, Kosaka K, Efthimiou O, Kawakami K, Furukawa TA & Mandai M (2023) Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia: A Systematic Review and Meta-analysis. Obstetrics and Gynecology, 142, 307-318. https://doi.org/10.1097/aog.0000000000005256 
  38. Ishida J, Murai T, Ueda K, Furukawa TA & Tanemura R (2023) Utility of a novel tablet computer software for memory impairment in participants with brain injuries: A randomized control trial. Neuropsychological Rehabilitation, 33, 85-102. https://doi.org/10.1080/09602011.2021.1987276 
  39. Kataoka Y, Yamamoto-Kataoka S, So R & Furukawa TA (2023) Beyond the Pass Mark: Accuracy of ChatGPT and Bing in the National Medical Licensure Examination in Japan. JMA J, 6, 536-538. https://doi.org/10.31662/jmaj.2023-0043 
  40. Kataoka Y, Taito S, Yamamoto N, So R, Tsutsumi Y, Anan K, Banno M, Tsujimoto Y, Wada Y, Sagami S, Tsujimoto H, Nihashi T, Takeuchi M, Terasawa T, Iguchi M, Kumasawa J, Ichikawa T, Furukawa R, Yamabe J & Furukawa TA (2023) An open competition involving thousands of competitors failed to construct useful abstract classifiers for new diagnostic test accuracy systematic reviews. Research Synthesis Methods, 14, 707-717. https://doi.org/10.1002/jrsm.1649 
  41. Kataoka Y, Banno M, Tsujimoto Y & Furukawa TA (2023) "Meta-epidemiological study" is a study in which the unit of analysis is a study, not a patient; response to Puljak et al. Journal of Clinical Epidemiology, 154, 219-220. https://doi.org/10.1016/j.jclinepi.2022.12.002 
  42. Kawashima H, Toyomoto R & Furukawa TA (2023) Some concerns about exclusion of participants. Brain Stimulation, 16, 1205. https://doi.org/10.1016/j.brs.2023.06.015 
  43. Kishimoto S, Watanabe N, Yamamoto Y, Imai T, Aida R, Germer C, Tamagawa-Mineoka R, Shimizu R, Hickman S, Nakayama Y, Etoh T, Sahker E, Carnie MB & Furukawa TA (2023) Efficacy of Integrated Online Mindfulness and Self-compassion Training for Adults With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatology, 159, 628-636. https://doi.org/10.1001/jamadermatol.2023.0975 
  44. Luo Y, Chalkou K, Funada S, Salanti G & Furukawa TA (2023) Estimating Patient-Specific Relative Benefit of Adding Biologics to Conventional Rheumatoid Arthritis Treatment: An Individual Participant Data Meta-Analysis. JAMA Network Open, 6, e2321398. https://doi.org/10.1001/jamanetworkopen.2023.21398 
  45. Luo Y & Furukawa TA (2023) Effect size calculation needs to be specified with details: comment on Ying et al. Psychological Medicine, 53, 4300-4301. https://doi.org/10.1017/S0033291722002057 
  46. Marx W, Penninx B, Solmi M, Furukawa TA, Firth J, Carvalho AF & Berk M (2023) Major depressive disorder. Nature Reviews Disease Primers, 9, 44. https://doi.org/10.1038/s41572-023-00454-1 
  47. Nakane S, Tanaka-Mizuno S, Nishiyama C, Kochi K, Yamamoto-Sasaki M, Takeuchi M, Ogawa Y, Doi Y, Arai M, Fujii Y, Matsunaga T, Furukawa TA & Kawakami K (2023) Trends in Prescribing Antipsychotics for Children and Adolescents in Japan: A Descriptive Epidemiological Study Using a Large-Scale Pharmacy Dataset. Child Psychiatry and Human Development, 54, 1250-1257. https://doi.org/10.1007/s10578-022-01330-x 
  48. Narita Z, DeVylder J, Yamasaki S, Ando S, Endo K, Miyashita M, Yamaguchi S, Usami S, Stanyon D, Knowles G, Hiraiwa-Hasegawa M, Furukawa TA, Kasai K & Nishida A (2023) Uncovering associations between gender nonconformity, psychosocial factors, and mental health in adolescents: a birth cohort study. Psychological Medicine, 1-10. https://doi.org/10.1017/s0033291723002623 
  49. Nikolakopoulou A, Chaimani A, Furukawa TA, Papakonstantinou T, Rücker G & Schwarzer G (2023) When does the placebo effect have an impact on network meta-analysis results? BMJ Evidence-Based Medicine. https://doi.org/10.1136/bmjebm-2022-112197 
  50. Noma H, Hamura Y, Gosho M & Furukawa TA (2023) Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression. Research Synthesis Methods, 14, 731-741. https://doi.org/10.1002/jrsm.1652 
  51. Noma H, Hamura Y, Sugasawa S & Furukawa TA (2023) Improved methods to construct prediction intervals for network meta-analysis. Research Synthesis Methods, 14, 794-806. https://doi.org/10.1002/jrsm.1651 
  52. Orri M, Gifuni AJ, Ougrin D, Boruff J, Cipriani A, Furukawa TA, Schaffer D, Del Giovane C, Inja A, Turecki G, Geoffroy MC & Cortese S (2023) Psychosocial interventions for the prevention of self-harm repetition: protocol for a systematic review and network meta-analysis. BMJ Open, 13, e072289. https://doi.org/10.1136/bmjopen-2023-072289 
  53. Ostinelli EG, Chiocchia V, Macleod M, Browning M, Harmer C, Siafis S, Stansfield C, Friedrich C, Wright S, Chikaura T, Milligan L, Thomas J, Moreno C, Furukawa TA, Seedat S, Potts J, Salanti G & Cipriani A (2023) Pro-dopaminergic pharmacological interventions for anhedonia in depression: protocol for a living systematic review of human and non-human studies [version 1; peer review: awaiting peer review]. Wellcome Open Research
  54. Papola D, Karyotaki E, Purgato M, Sijbrandij M, Tedeschi F, Cuijpers P, Orestis E, Furukawa TA, Patel V & Barbui C (2023) Dismantling and personalising task-sharing psychosocial interventions for common mental disorders: a study protocol for an individual participant data component network meta-analysis. BMJ Open, 13, e077037. https://doi.org/10.1136/bmjopen-2023-077037 
  55. Papola D, Miguel C, Mazzaglia M, Franco P, Tedeschi F, Romero SA, Patel AR, Ostuzzi G, Gastaldon C, Karyotaki E, Harrer M, Purgato M, Sijbrandij M, Patel V, Furukawa TA, Cuijpers P & Barbui C (2023) Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2023.3971 
  56. Papola D, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C, Pompoli A, Pauley D, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers P & Barbui C (2023) CBT treatment delivery formats for panic disorder: a systematic review and network meta-analysis of randomised controlled trials. Psychological Medicine, 53, 614-624. https://doi.org/10.1017/S0033291722003683 
  57. Patel V, Fancourt D, Furukawa TA & Kola L (2023) Reimagining the journey to recovery: The COVID-19 pandemic and global mental health. PLoS Medicine, 20, e1004224. https://doi.org/10.1371/journal.pmed.1004224 
  58. Puac-Polanco V, Ziobrowski HN, Ross EL, Liu H, Turner B, Cui R, Leung LB, Bossarte RM, Bryant C, Joormann J, Nierenberg AA, Oslin DW, Pigeon WR, Post EP, Zainal NH, Zaslavsky AM, Zubizarreta JR, Luedtke A, Kennedy CJ, Cipriani A, Furukawa TA & Kessler RC (2023) Development of a model to predict antidepressant treatment response for depression among Veterans. Psychological Medicine, 53, 5001-5011. https://doi.org/10.1017/S0033291722001982 
  59. Ralovska S, Koychev I, Marinov P, Furukawa TA, Mulsant B & Cipriani A (2023) Brexpiprazole versus placebo or other antidepressive agents for treating depression. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD013866.pub2 
  60. Sato A, Moriyama T, Watanabe N, Maruo K & Furukawa TA (2023) Development and validation of a prediction model for rehospitalization among people with schizophrenia discharged from acute inpatient care. Frontiers in Psychiatry, 14, 1242918. https://doi.org/10.3389/fpsyt.2023.1242918 
  61. Seki T, Aki M, Furukawa TA, Kawashima H, Miki T, Sawaki Y, Ando T, Katsuragi K, Kawashima T, Ueno S, Miyagi T, Noma S, Tanaka S & Kawakami K (2023) Electronic Health Record-Nested Reminders for Serum Lithium Level Monitoring in Patients With Mood Disorder: Randomized Controlled Trial. Journal of Medical Internet Research, 25, e40595. https://doi.org/10.2196/40595 
  62. Seo M, Furukawa TA, Karyotaki E & Efthimiou O (2023) Developing prediction models when there are systematically missing predictors in individual patient data meta-analysis. Research Synthesis Methods, 14, 455-467. https://doi.org/10.1002/jrsm.1625 
  63. Setkowski K, Palantza C, van Ballegooijen W, Gilissen R, Oud M, Cristea IA, Noma H, Furukawa TA, Arntz A, van Balkom A & Cuijpers P (2023) Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychological Medicine, 53, 3261-3280. https://doi.org/10.1017/S0033291723000685 
  64. Shiraishi N, Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Tajika A, Suga H, Ito H, Sumi M, Muto T, Ichikawa H, Ikegawa M, Watanabe T, Sahker E, Uwatoko T, Noma H, Horikoshi M, Iwami T & Furukawa TA (2023) Three types of university students with subthreshold depression characterized by distinctive cognitive behavioral skills. Cognitive Behaviour Therapy, 1-13. https://doi.org/10.1080/16506073.2023.2288557 
  65. Shiraishi N, Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Tajika A, Watanabe T, Sahker E, Uwatoko T, Shimamoto T, Iwami T & Furukawa TA (2023) Dynamics of depressive states among university students in Japan during the COVID-19 pandemic: an interrupted time series analysis. Annals of General Psychiatry, 22, 38. https://doi.org/10.1186/s12991-023-00468-9 
  66. Tada M, Matano H, Azuma H, Kano KI, Maeda S, Fujino S, Yamada N, Uzui H, Tada H, Maeno K, Shimada Y, Yoshida H, Ando M, Ichihashi T, Murakami Y, Homma Y, Funakoshi H, Obunai K, Matsushima A, Ohte N, Takeuchi A, Takada Y, Matsukubo S, Ando H, Furukawa Y, Kuriyama A, Fujisawa T, Chapman AR, Mills NL, Hayashi H, Watanabe N & Furukawa TA (2023) Comprehensive validation of early diagnostic algorithms for myocardial infarction in the emergency department. QJM: An International Journal of Medicine, hcad242. https://doi.org/10.1093/qjmed/hcad242 
  67. Tajika A, Tsujimoto Y, Onishi A, Tsutsumi Y, Funada S, Ogawa Y, Takeshima N, Hayasaka Y, Iwakami N & Furukawa TA (2023) Twenty-year follow-up of promising clinical studies reported in highly circulated newspapers: a meta-epidemiological study. BMJ Health Care Informatics, 30. https://doi.org/10.1136/bmjhci-2023-100768 
  68. Tajika A, Furukawa TA, Shinohara K, Kikuchi S, Toyomoto R, Furukawa Y, Ito M, Yoshida K, Honda Y, Takayama T, Schneider-Thoma J & Leucht S (2023) Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review. BMJ Ment Health, 26. https://doi.org/10.1136/bmjment-2023-300654 
  69. Tonia T, Buitrago-Garcia D, Peter NL, Mesa-Vieira C, Li T, Furukawa TA, Cipriani A, Leucht S, Low N & Salanti G (2023) Tool to assess risk of bias in studies estimating the prevalence of mental health disorders (RoB-PrevMH). BMJ Ment Health, 26. https://doi.org/10.1136/bmjment-2023-300694 
  70. Toyomoto R, Sakata M, Yoshida K, Luo Y, Nakagami Y, Uwatoko T, Shimamoto T, Sahker E, Tajika A, Suga H, Ito H, Sumi M, Muto T, Ito M, Ichikawa H, Ikegawa M, Shiraishi N, Watanabe T, Watkins ER, Noma H, Horikoshi M, Iwami T & Furukawa TA (2023) Prognostic factors and effect modifiers for personalisation of internet-based cognitive behavioural therapy among university students with subthreshold depression: A secondary analysis of a factorial trial. Journal of Affective Disorders, 322, 156-162. https://doi.org/10.1016/j.jad.2022.11.024 
  71. Tsutsumi Y, Tsujimoto Y, Tajika A, Omae K, Fujii T, Onishi A, Kataoka Y, Katsura M, Noma H, Sahker E, Ostinelli EG & Furukawa TA (2023) Proportion attributable to contextual effects in general medicine: a meta-epidemiological study based on Cochrane reviews. BMJ Evidence-Based Medicine, 28, 40-47. https://doi.org/10.1136/bmjebm-2021-111861 
  72. Uchida M, Furukawa TA, Yamaguchi T, Imai F, Momino K, Katsuki F, Sakurai N, Miyaji T, Horikoshi M, Iwata H, Zenda S, Iwatani T, Ogawa A, Inoue A, Abe M, Toyama T, Uchitomi Y, Matsuoka H, Noma H & Akechi T (2023) Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial. Trials, 24, 344. https://doi.org/10.1186/s13063-023-07307-y 
  73. Wang Y, Devji T, Carrasco-Labra A, King MT, Terluin B, Terwee CB, Walsh M, Furukawa TA & Guyatt GH (2023) A step-by-step approach for selecting an optimal minimal important difference. BMJ, 381, e073822. https://doi.org/10.1136/bmj-2022-073822 
  74. Wang Y, Devji T, Carrasco-Labra A, Qasim A, Hao Q, Kum E, Devasenapathy N, King MT, Terluin B, Terwee CB, Walsh M, Furukawa TA, Tsujimoto Y & Guyatt GH (2023) An extension minimal important difference credibility item addressing construct proximity is a reliable alternative to the correlation item. Journal of Clinical Epidemiology, 157, 46-52. https://doi.org/10.1016/j.jclinepi.2023.03.001 
  75. Wright S, Furukawa TA, Macleod M, Simple O, Elugbadebo O, Chiocchia V, Friedrich C, Ostinelli EG, Potts J, Ramage F, Siafis S, Stainsfield C, Tinsdeall F, Thomas J, Cipriani A, Salanti G & Seedat S (2023) Mechanisms through which exercise reduces symptom severity and/or functional impairment in posttraumatic stress disorder (PTSD): Protocol for a living systematic review of human and non-human studies [version 1; peer review: awaiting peer review]. Wellcome Open Research.
  76. Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S & Watanabe N (2023) Bladder training for treating overactive bladder in adults. Cochrane Database of Systematic Reviews, 10, Cd013571. https://doi.org/10.1002/14651858.CD013571.pub2 
  77. Funada S, Luo Y, Nishioka N & Yoshioka T (2023) Cardiovascular risk in systemic autoimmune diseases. Lancet, 401, 21. https://doi.org/10.1016/S0140-6736(22)02474-6  
  78. Luo Y, Heneghan C & Persaud N (2023) Catalogue of bias: novelty bias. BMJ Evidence-Based Medicine, bmjebm-2022-112215. https://doi.org/10.1136/bmjebm-2022-112215  
  79. Kataoka Y & So R (2023) Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine. New England Journal of Medicine, 388, 2399-2400. https://doi.org/10.1056/NEJMc2305286  

2022

  1.   Carrasco-Labra A, Devji T, Qasim A, Phillips M, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, Vernooij RWM, Huang H, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa TA, Nesrallah G, Schunemann HJ, Bhandari M, Thabane L & Guyatt GH (2022) Serious reporting deficiencies exist in minimal important difference studies: Current state and suggestions for improvement. Journal of Clinical Epidemiology, 150, 25-32.
  2.  Chevance A, Ravaud P, Cornelius V, Mayo-Wilson E & Furukawa TA (2022) Designing clinically useful psychopharmacological trials: Challenges and ways forward. The Lancet Psychiatry.
  3.  Czobor P, Sebe B, Acsai K, Barabássy Á, Laszlovszky I, Németh G, Furukawa TA & Leucht S (2022) What is the minimum clinically important change in negative symptoms of schizophrenia? Panss based post-hoc analyses of a phase iii clinical trial. Frontiers in  Psychiatry, 13, 816339.
  4.  Efthimiou O, Seo M, Karyotaki E, Cuijpers P, Furukawa TA, Schwarzer G, Rücker G & Mavridis D (2022) Bayesian models for aggregate and individual patient data component network meta-analysis. Statistics in Medicine, 41, 2586-2601.
  5.  Elsaesser M, Furukawa TA & Schramm E (2022) Why one answer is not always enough: Reply to "cbasp may not be superior to other treatments for chronic depression". Journal of Affective Disorders, 312, 144-145.
  6.  Fujii T, Salanti G, Belletti A, Bellomo R, Carr A, Furukawa TA, Luethi N, Luo Y, Putzu A, Sartini C, Tsujimoto Y, Udy AA, Yanase F & Young PJ (2022) Effect of adjunctive vitamin c, glucocorticoids, and vitamin B1 on longer-term mortality in adults with sepsis or septic shock: A systematic review and a component network meta-analysis. Intensive Care Medicine, 48, 16-24.
  7.  Funada S, Luo Y, Yoshioka T, Setoh K, Tabara Y, Negoro H, Yoshimura K, Matsuda F, Efthimiou O, Ogawa O, Furukawa TA, Kobayashi T & Akamatsu S (2022) Development and validation of prediction model for incident overactive bladder: The nagahama study. International Journal of Urology, 29, 748-756.
  8.  Funada S, Luo Y, Kataoka Y, Yoshioka T, Fujita Y, Yoshida S, Katsura M, Tada M, Nishioka N, Nakamura Y & Furukawa TA (2022) Inadequate reporting of adjudicators in open-label trials of anticancer drugs between 2017 and 2021: A methodological review. Journal of Clinical Epidemiology, 150, 80-89. https://www.sciencedirect.com/science/article/pii/S0895435622001718
  9.  Furukawa TA & Bighelli I (2022) Digital aids for relapse prevention in schizophrenia. Lancet Psychiatry, 9, 424-425. https://www.ncbi.nlm.nih.gov/pubmed/35569494
  10.  Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G & Ostinelli EG (2022) Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: Preliminary findings based on a systematic review and dose-effect meta-analysis. British Journal of Psychiatry, 221, 440-447. <Go to ISI>://WOS:000744687200001
  11.  Hamza T, Furukawa TA, Orsini N, Cipriani A & Salanti G (2022) Dose-effect meta-analysis for psychopharmacological interventions using randomised data. Evidence-Based Mental Health, 25, 1-6.
  12.  Herrman H, Patel V, Kieling C, Berk M, Buchweitz C, Cuijpers P, Furukawa TA, Kessler RC, Kohrt BA, Maj M, McGorry P, Reynolds CF, 3rd, Weissman MM, Chibanda D, Dowrick C, Howard LM, Hoven CW, Knapp M, Mayberg HS, Penninx B, Xiao S, Trivedi M, Uher R, Vijayakumar L & Wolpert M (2022) Time for united action on depression: A lancet-world psychiatric association commission. Lancet, 399, 957-1022. https://www.ncbi.nlm.nih.gov/pubmed/35180424
  13.  Hwang CY, Takano T, So R, Sahker E, Kawakami S, Livingstone C, Takiguchi N, Ono-Kihara M, Kihara M & Furukawa TA (2022) Prevalence of gambling disorder and its correlates among homeless men in osaka city, japan. Journal of Gambling Studies. <Go to ISI>://WOS:000811475700001
  14.  Imai H, Tajika A, Narita H, Yoshinaga N, Kimura K, Nakamura H, Takeshima N, Hayasaka Y, Ogawa Y & Furukawa T (2022) Unguided computer-assisted self-help interventions without human contact in patients with obsessive-compulsive disorder: Systematic review and meta-analysis. Journal of Medical Internet Research, 24.
  15.  Kabeya Y, Goto A, Hayashino Y, Suzuki H, Furukawa TA, Yamazaki K, Izumi K & Noda M (2022) Psychological and situational factors affecting dropout from regular visits in diabetes practice: The japan diabetes outcome intervention trial-2 large scale trial 004 (j-doit2-lt004). Japan Medical Association Journal, 5, 427-437.
  16.  Karyotaki E, Araya R, Kessler RC, Waqas A, Bhana A, Rahman A, Matsuzaka CT, Miguel C, Lund C, Garman EC, Nakimuli-Mpungu E, Petersen I, Naslund JA, Schneider M, Sikander S, Jordans MJD, Abas M, Slade P, Walters S, Brugha TS, Furukawa TA, Amanvermez Y, Mello MF, Wainberg ML, Cuijpers P & Patel V (2022) Association of task-shared psychological interventions with depression outcomes in low- and middle-income countries: A systematic review and individual patient data meta-analysis. JAMA Psychiatry, 79, 430-443.
  17.  Kataoka Y, Banno M, Tsujimoto Y & Furukawa TA (2022) “Meta-epidemiological study” is a study in which the unit of analysis is a study, not a patient; response to puljak et al. Journal of Clinical Epidemiology. https://www.sciencedirect.com/science/article/pii/S0895435622003183
  18.  Kataoka Y, Banno M, Tsujimoto Y, Ariie T, Taito S, Suzuki T, Oide S & Furukawa TA (2022) Retracted randomized controlled trials were cited and not corrected in systematic reviews and clinical practice guidelines. Journal of Clinical Epidemiology, 150, 90-97. https://doi.org/10.1016/j.jclinepi.2022.06.015
  19.  Kessler RC, Furukawa TA, Kato T, Luedtke A, Petukhova M, Sadikova E & Sampson NA (2022) An individualized treatment rule to optimize probability of remission by continuation, switching, or combining antidepressant medications after failing a first-line antidepressant in a two-stage randomized trial. Psychological Medicine, 52, 3371-3380. https://www.cambridge.org/core/article/an-individualized-treatment-rule-to-optimize-probability-of-remission-by-continuation-switching-or-combining-antidepressant-medications-after-failing-a-firstline-antidepressant-in-a-twostage-randomized-trial/DDEFA9F0735147100E0BE81491B362C8
  20.  Kikuchi S, Oe Y, Ito Y, Sozu T, Sasaki Y, Sakata M, Luo Y, Sahker E, Horikoshi M, Seno H & Furukawa TA (2022) Group cognitive-behavioral therapy with interoceptive exposure for drug-refractory irritable bowel syndrome: A randomized controlled trial. American Journal of Gastroenterology, 117, 668-677. <Go to ISI>://WOS:000775859200023
  21.  Leucht S, Siafis S, Engel RR, Schneider-Thoma J, Bighelli I, Cipriani A, Furukawa TA & Davis JM (2022) How efficacious are antipsychotic drugs for schizophrenia? An interpretation based on 13 effect size indices. Schizophrenia Bulletin, 48, 27-36.
  22.  Leucht S, Li CB, Davis JM, Bighelli I, Zhu YK & Furukawa TA (2022) About the issue of including or excluding studies from China in systematic reviews. Schizophrenia Research, 240, 162-163. <Go to ISI>://WOS:000769804400023
  23.  Levine SZ, Goldberg Y, Yoshida K, Samara M, Cipriani A, Iwatsubo T, Leucht S & Furukawa TA (2022) Early- and subsequent- response of cognitive functioning in alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. Journal of Psychiatric Research, 148, 159-164.
  24.  Lin Y-H, Sahker E, Shinohara K, Horinouchi N, Ito M, Lelliott M, Cipriani A, Tomlinson A, Baethge C & Furukawa TA (2022) Assessment of blinding in randomized controlled trials of antidepressants for depressive disorders 2000–2020: A systematic review and meta-analysis. eClinicalMedicine, 50, 101505. https://www.sciencedirect.com/science/article/pii/S2589537022002358
  25.  Luo Y, Funada S, Yoshida K, Noma H, Sahker E & Furukawa TA (2022) Large variation existed in standardized mean difference estimates using different calculation methods in clinical trials. Journal of Clinical Epidemiology, 149, 89-97.
  26.  Luo Y & Furukawa TA (2022) Effect size calculation needs to be specified with details: Comment on ying et al. Psychological Medicine. <Go to ISI>://WOS:000827409100001
  27.  Muit JJ, van Eijndhoven PFP, Cipriani A, Dalhuisen I, van Bronswijk S, Furukawa TA & Ruhe HG (2022) Efficacy and acceptability of next step treatment strategies in adults with treatment-resistant major depressive disorder: Protocol for systematic review and network meta-analysis. BMJ Open, 12, e056777. https://www.ncbi.nlm.nih.gov/pubmed/35437250
  28.  Noma H, Nagashima K, Kato S, Teramukai S & Furukawa TA (2022) Meta-analysis using flexible random-effects distribution models. Journal of Epidemiology, 32, 441-448. https://www.ncbi.nlm.nih.gov/pubmed/33583933
  29.  Omae K, Onishi A, Sahker E & Furukawa TA (2022) Us food and drug administration accelerated approval program for nononcology drug indications between 1992 and 2018. JAMA Network Open, 5, e2230973.
  30.  Ostinelli EG, Efthimiou O, Naci H, Furukawa TA, Leucht S, Salanti G, Wainwright L, Zangani C, De Crescenzo F, Smith K, Stevens K, Liu Q & Cipriani A (2022) Vitruvian plot: A visualisation tool for multiple outcomes in network meta-analysis. Evidence-Based Mental Health, 25, e65-e70.
  31.  Papola D, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C, Pompoli A, Pauley D, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers P & Barbui C (2022) Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: Systematic review and network meta-analysis of randomised controlled trials. British Journal of Psychiatry, 221, 507-519. <Go to ISI>://WOS:000744721600001
  32.  Puac-Polanco V, Ziobrowski HN, Ross EL, Liu H, Turner B, Cui RF, Leung LB, Bossarte RM, Bryant C, Joormann J, Nierenberg AA, Oslin DW, Pigeon WR, Post EP, Zainal NH, Zaslavsky AM, Zubizarreta JR, Luedtke A, Kennedy CJ, Cipriani A, Furukawa TA & Kessler RC (2022) Development of a model to predict antidepressant treatment response for depression among veterans. Psychological Medicine. <Go to ISI>://WOS:000825462100001
  33.  Rodolico A, Bighelli I, Avanzato C, Concerto C, Cutrufelli P, Mineo L, Schneider-Thoma J, Siafis S, Signorelli MS, Wu H, Wang D, Furukawa TA, Pitschel-Walz G, Aguglia E & Leucht S (2022) Family interventions for relapse prevention in schizophrenia: A systematic review and network meta-analysis. The Lancet Psychiatry. https://www.sciencedirect.com/science/article/pii/S2215036621004375
  34.  Rotstein A, Levine SZ, Samara M, Yoshida K, Goldberg Y, Cipriani A, Iwatsubo T, Leucht S & Furukawa TA (2022) Cognitive impairment networks in alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. European Neuropsychopharmacology, 57, 50-58.
  35.  Sahker E, Luo Y, Sakata M, Toyomoto R, Hwang C, Yoshida K, Watanabe N & Furukawa TA (2022) Efficacy of brief intervention for unhealthy drug use in outpatient medical care: A systematic review and meta-analysis. Journal of General Internal Medicine, 37, 2041-2049.
  36.  Sahker E, Pro G, Sakata M, Poudyal H, Jordan A & Furukawa TA (2022) Factors supporting substance use improvement for black americans: A population health observational study. Drug and Alcohol Dependence, 234.
  37.  Sahker E, Onishi A, Ostinelli EG, Tsutsumi Y, Omae K & Furukawa TA (2022) Substance use disorder treatment success: Assessing patient-reported use improvement and provider-evaluated treatment completion. Addiction Research & Theory, 30, 199-206. <Go to ISI>://WOS:000713889600001
  38.  Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Uwatoko T, Shimamoto T, Tajika A, Suga H, Ito H, Sumi M, Muto T, Ito M, Ichikawa H, Ikegawa M, Shiraishi N, Watanabe T, Sahker E, Ogawa Y, Hollon SD, Collins LM, Watkins ER, Wason J, Noma H, Horikoshi M, Iwami T & Furukawa TA (2022) Components of smartphone cognitive-behavioural therapy for subthreshold depression among 1093 university students: A factorial trial. Evidence-Based Mental Health. <Go to ISI>://WOS:000797906700001
  39.  Salanti G, Peter N, Tonia T, Holloway A, White IR, Darwish L, Low N, Egger M, Haas AD, Fazel S, Kessler RC, Herrman H, Kieling C, De Quervain DJF, Vigod SN, Patel V, Li T, Cuijpers P, Cipriani A, Furukawa TA, Leucht S, Sambo AU, Onishi A, Sato A, Rodolico A, Oliveira Solis AC, Antoniou A, Kapfhammer A, Ceraso A, O'Mahony A, Lasserre AM, Ipekci AM, Concerto C, Zangani C, Igwesi-Chidobe C, Diehm C, Demir DD, Wang D, Ostinelli EG, Sahker E, Beraldi GH, Erzin G, Nelson H, Elkis H, Imai H, Wu H, Kamitsis I, Filis I, Michopoulos I, Bighelli I, Hong JSW, Ballesteros J, Smith KA, Yoshida K, Omae K, Trivella M, Tada M, Reinhard MA, Ostacher MJ, Müller M, Jaramillo NG, Ferentinos PP, Toyomoto R, Cortese S, Kishimoto S, Covarrubias-Castillo SA, Siafis S, Thompson T, Karageorgiou V, Chiocchia V, Zhu Y & Honda Y (2022) The impact of the covid-19 pandemic and associated control measures on the mental health of the general population : A systematic review and dose-response meta-analysis. Annals of Internal Medicine, 175, 1560-1571.
  40.  Sato A, Watanabe N, Maruo K, Moriyama T & Furukawa TA (2022) Psychotic relapse in people with schizophrenia within 12 months of discharge from acute inpatient care: Protocol for development and validation of a prediction model based on a retrospective cohort study in three psychiatric hospitals in japan. Diagnostic and Prognostic Research, 6, 20.
  41.  Schneider-Thoma J, Chalkou K, Dörries C, Bighelli I, Ceraso A, Huhn M, Siafis S, Davis JM, Cipriani A, Furukawa TA, Salanti G & Leucht S (2022) Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: A systematic review and network meta-analysis. The Lancet, 399, 824-836. https://www.sciencedirect.com/science/article/pii/S0140673621019978
  42.  Shinohara Y, Yamamoto K, Ito M, Sakata M, Koizumi S, Hashisako M, Sato M, Wannous M, Stoyanov SR, Nakajima J & Furukawa TA (2022) Development and validation of the japanese version of the uMARS (user version of the mobile app rating system). International Journal of Medical Informatics, 165.
  43.  Tada M, Yamada N, Matsumoto T, Takeda C, Furukawa TA & Watanabe N (2022) Ultrasound guidance versus landmark method for peripheral venous cannulation in adults. Cochrane Database of Systematic Reviews. https://doi.org//10.1002/14651858.CD013434.pub2
  44. Toyomoto R, Sakata M, Yoshida K, Luo Y, Nakagami Y, Iwami T, Aoki S, Irie T, Sakano Y, Suga H, Sumi M, Ichikawa H, Watanabe T, Tajika A, Uwatoko T, Sahker E & Furukawa TA (2022) Validation of the japanese big five scale short form in a university student sample. Frontiers in Psychology, 13. https://www.frontiersin.org/article/10.3389/fpsyg.2022.862646
  45.  Toyomoto R, Funada S & Furukawa TA (2022) Some concerns about imputation methods for missing data. JAMA Psychiatry.
  46.  Tsujimoto Y, Fujii T, Tsutsumi Y, Kataoka Y, Tajika A, Okada Y, Carrasco-Labra A, Devji T, Wang Y, Guyatt GH & Furukawa TA (2022) Minimal important changes in standard deviation units are highly variable and no universally applicable value can be determined. Journal of Clinical Epidemiology, 145, 92-100.
  47.  Tsujimoto Y, Tsutsumi Y, Kataoka Y, Banno M & Furukawa TA (2022) The inclusion of outcomes in search strategies for cochrane reviews: Authors' reply. Journal of Clinical Epidemiology, 142, 324-325. <Go to ISI>://WOS:000820490800022
  48.  Turner EH, Cipriani A, Furukawa TA, Salanti G & de Vries YA (2022) Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials. PLoS Medicine, 19, e1003886.
  49.  Yamamoto K, Ito M, Sakata M, Koizumi S, Hashisako M, Sato M, Stoyanov SR & Furukawa TA (2022) Japanese version of the mobile app rating scale (MARS): Development and validation. JMIR Mhealth Uhealth, 10, e33725.
  50.  Yoshida K, Seo M, Luo Y, Sahker E, Cipriani A, Leucht S, Iwatsubo T, Efthimiou O & Furukawa TA (2022) Personalized prediction of alzheimer's disease and its treatment effects by donepezil: An individual participant data meta-analysis of eight randomized controlled trials. Journal of Alzheimer's Disease, 89, 1143-1157. https://www.ncbi.nlm.nih.gov/pubmed/35988219

 

2021

  1. Garcia FCC, Hirao A, Tajika A, Furukawa TA, Ikeda K & Yoshimoto J (2021) Leveraging Longitudinal Lifelog Data Using Survival Models for Predicting Risk of Relapse among Patients with Depression in Remission. Annu Int Conf IEEE Eng Med Biol Soc, 2021, 2455-2458. 
  2. Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G, Hansen WP, Schneider-Thoma J, Siafis S, Wu H, Wang D, Salanti G, Furukawa TA, Barbui C & Leucht S (2021) Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry, 8, 969-980. 
  3. Carrasco-Labra A, Devji T, Qasim A, Phillips MR, Wang Y, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, Hao Q, Wong V, Ye Z, Yao L, Vernooij RWM, Huang H, Zeng L, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa TA, Nesrallah G, Schünemann HJ, Bhandari M, Thabane L & Guyatt GH (2021) Minimal important difference estimates for patient-reported outcomes: A systematic survey. Journal of Clinical Epidemiology, 133, 61-71. 
  4. Carrozzino D, Patierno C, Guidi J, Berrocal Montiel C, Cao J, Charlson ME, Christensen KS, Concato J, De Las Cuevas C, de Leon J, Eory A, Fleck MP, Furukawa TA, Horwitz RI, Nierenberg AA, Rafanelli C, Wang H, Wise TN, Sonino N & Fava GA (2021) Clinimetric Criteria for Patient-Reported Outcome Measures. Psychotherapy and Psychosomatics, 90, 222-232.  
  5. Chiocchia V, Nikolakopoulou A, Higgins JPT, Page MJ, Papakonstantinou T, Cipriani A, Furukawa TA, Siontis GCM, Egger M & Salanti G (2021) ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis. BMC Medicine, 19. 
  6. Ciharova M, Furukawa TA, Efthimiou O, Karyotaki E, Miguel C, Noma H, Cipriani A, Riper H & Cuijpers P (2021) Cognitive restructuring, behavioral activation and cognitive-behavioral therapy in the treatment of adult depression: A network meta-analysis. Journal of Consulting and Clinical Psychology, 89, 563-574. 
  7. Collister D, Bangdiwala S, Walsh M, Mian R, Lee SF, Furukawa TA & Guyatt G (2021) Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses. Journal of Clinical Epidemiology, 134, 95-102. 
  8. Cuijpers P, Griffin JW & Furukawa TA (2021) The lack of statistical power of subgroup analyses in meta-analyses: a cautionary note. Epidemiology and Psychiatric Sciences, 30. Cuijpers P, Karyotaki E, Ciharova M, Miguel C, Noma H & Furukawa TA (2021) The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatrica Scandinavica, 144, 288-299. https://www.ncbi.nlm.nih.gov/pubmed/34107050 
  9. Cuijpers P, Oud M, Karyotaki E, Noma H, Quero S, Cipriani A, Arroll B & Furukawa TA (2021) Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Annals of Family Medicine, 19, 262-270. 
  10. Cuijpers P, Pineda BS, Quero S, Karyotaki E, Struijs SY, Figueroa CA, Llamas JA, Furukawa TA & Muñoz RF (2021) Psychological interventions to prevent the onset of depressive disorders: A meta-analysis of randomized controlled trials. Clinical Psychology Review, 83, 101955. 
  11. Cuijpers P, Quero S, Noma H, Ciharova M, Miguel C, Karyotaki E, Cipriani A, Cristea I & Furukawa TA (2021) Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types. World Psychiatry, 20, 283-293. 
  12. Cuijpers P, Smit F & Furukawa TA (2021) Most at-risk individuals will not develop a mental disorder: the limited predictive strength of risk factors. World Psychiatry, 20, 224-225. 
  13. Funada S, Luo Y & Furukawa TA (2021) Considerations regarding a network meta-analysis of systemic treatments for metastatic castration-sensitive prostate cancer. JAMA Oncology. https://www.ncbi.nlm.nih.gov/pubmed/33983384 
  14. Funada S, Luo Y, Yoshioka T, Setoh K, Tabara Y, Negoro H, Akamatsu S, Yoshimura K, Matsuda F, Furukawa TA, Efthimiou O & Ogawa O (2021) Protocol for development and validation of a prediction model for 5-year risk of incident overactive bladder in the general population: the Nagahama study. BMC Urology, 21. 
  15. Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Uozumi R, Kishimoto S, Ichioka K, Segawa T, Furukawa TA & Ogawa O (2021) Clinical feasibility and acceptability of adding cognitive behavioral therapy to pharmacotherapy for drug-resistant overactive bladder in women: A single-arm pilot study. Low Urin Tract Symptoms, 13, 69-78. https://www.ncbi.nlm.nih.gov/pubmed/32618414 
  16. Funada S, Yoshioka T & Luo Y (2021) Re: Guohua Zeng, Chao Cai, Xianzhong Duan, et al. Mini Percutaneous Nephrolithotomy Is a Noninferior Modality to Standard Percutaneous Nephrolithotomy for the Management of 20-40mm Renal Calculi: A Multicenter Randomized Controlled Trial. Eur Urol 2021;79:114-21. European Urology, 79, e60-e61. 
  17. Funada S & Luo Y (2021) Implementing Group-Based Pelvic Floor Muscle Training in Clinical Practice. JAMA Intern Med, 181, 405-406. 
  18. Funada S, Yoshioka T & Luo Y (2021) Re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol 2020;78:701-10. European Urology, 79, e87-e88. 
  19. Funada S, Yoshioka T & Luo Y (2021) Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer. JAMA Oncol, 7, 633-634. 
  20. Funada S, Yoshioka T & Luo Y (2021) Re: Cosimo De Nunzio, Benjamin Brucker, Thomas Bschleipfer, et al. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. Eur Urol 2021;79:492-504. European Urology, 79, e145-e146. 
  21. Funada S & Luo Y (2021) Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. Lancet Oncology, 22, e236. 
  22. Yoshioka T, Funada S & Luo Y (2021) The Inherent Problems With the Generalizability of the CALL Score: Towards Reliable Clinical Prediction Models for Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 73, e2818. 
  23. Yoshioka T, Funada S & Luo Y (2021) Systematic Review and Meta-Analysis Comparing Percutaneous Nephrolithotomy, Retrograde Intrarenal Surgery and Shock Wave Lithotripsy for Lower Pole Renal Stones Less Than 2 cm in Maximum Diameter. Letter. Journal of Urology, 205, 1843-1844.
  24. Furukawa TA, Levine SZ, Buntrock C & Cuijpers P (2021) Increasing the clinical interpretability of PHQ-9 through equipercentile linking with health utility values by EQ-5D-3L. Evidence-Based Mental Health, 24, e6.  
  25. Furukawa TA, Levine SZ, Buntrock C, Ebert DD, Gilbody S, Brabyn S, Kessler D, Björkelund C, Eriksson M, Kleiboer A, van Straten A, Riper H, Montero-Marin J, Garcia-Campayo J, Phillips R, Schneider J, Cuijpers P & Karyotaki E (2021) How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D. Evidence-Based Mental Health, 24, 97-101. https://ebmh.bmj.com/content/24/3/97 
  26. Furukawa TA, Shinohara K, Sahker E, Karyotaki E, Miguel C, Ciharova M, Bockting CLH, Breedvelt Josefien JF, Tajika A, Imai H, Ostinelli EG, Sakata M, Toyomoto R, Kishimoto S, Ito M, Furukawa Y, Cipriani A, Hollon SD & Cuijpers P (2021) Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry, 20, 387-396. https://doi.org/10.1002/wps.20906 
  27. Furukawa TA, Suganuma A, Ostinelli EG, Andersson G, Beevers CG, Shumake J, Berger T, Boele FW, Buntrock C, Carlbring P, Choi I, Christensen H, Mackinnon A, Dahne J, Huibers MJH, Ebert DD, Farrer L, Forand NR, Strunk DR, Ezawa ID, Forsell E, Kaldo V, Geraedts A, Gilbody S, Littlewood E, Brabyn S, Hadjistavropoulos HD, Schneider LH, Johansson R, Kenter R, Kivi M, Björkelund C, Kleiboer A, Riper H, Klein JP, Schröder J, Meyer B, Moritz S, Bücker L, Lintvedt O, Johansson P, Lundgren J, Milgrom J, Gemmill AW, Mohr DC, Montero-Marin J, Garcia-Campayo J, Nobis S, Zarski AC, O'Moore K, Williams AD, Newby JM, Perini S, Phillips R, Schneider J, Pots W, Pugh NE, Richards D, Rosso IM, Rauch SL, Sheeber LB, Smith J, Spek V, Pop VJ, Ünlü B, van Bastelaar KMP, van Luenen S, Garnefski N, Kraaij V, Vernmark K, Warmerdam L, van Straten A, Zagorscak P, Knaevelsrud C, Heinrich M, Miguel C, Cipriani A, Efthimiou O, Karyotaki E & Cuijpers P (2021) Dismantling, optimising, and personalising internet cognitive behavioural therapy for depression: a systematic review and component network meta-analysis using individual participant data. Lancet Psychiatry, 8, 500-511. 
  28. Hamaguchi Y, Noma H, Nagashima K, Yamada T & Furukawa TA (2021) Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis. Biometrical Journal, 63, 394-405. https://www.ncbi.nlm.nih.gov/pubmed/33164247 
  29. Hamza T, Cipriani A, Furukawa TA, Egger M, Orsini N & Salanti G (2021) A Bayesian dose-response meta-analysis model: A simulations study and application. Statistical Methods in Medical Research, 30, 1358-1372. https://www.ncbi.nlm.nih.gov/pubmed/33504274 
  30. Imai H & Furukawa TA (2021) The risk perception against COVID-19 and outpatients' anxiety of visiting the clinic during COVID-19 pandemic. Psychiatry and Clinical Neurosciences. https://www.ncbi.nlm.nih.gov/pubmed/33792115 
  31. Imai H & Furukawa TA (2021) Psychological impact of masks and infection-prevention plastic partitions on anxiety for infection and patient-doctor relationships during COVID-19 pandemic. Primary Care Companion CNS Disorders, 23, 21m02921. 
  32. Imai H, Noma H & Furukawa TA (2021) Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients. European Archives of Psychiatry and Clinical Neuroscience, 271, 521-526. 
  33. Karyotaki E, Efthimiou O, Miguel C, Bermpohl FMG, Furukawa TA, Cuijpers P, Riper H, Patel V, Mira A, Gemmil AW, Yeung AS, Lange A, Williams AD, Mackinnon A, Geraedts A, van Straten A, Meyer B, Björkelund C, Knaevelsrud C, Beevers CG, Botella C, Strunk DR, Mohr DC, Ebert DD, Kessler D, Richards D, Littlewood E, Forsell E, Feng F, Wang F, Andersson G, Hadjistavropoulos H, Christensen H, Ezawa ID, Choi I, Rosso IM, Klein JP, Shumake J, Garcia-Campayo J, Milgrom J, Smith J, Montero-Marin J, Newby JM, Bretón-López J, Schneider J, Vernmark K, Bücker L, Sheeber LB, Warmerdam L, Farrer L, Heinrich M, Huibers MJH, Kivi M, Kraepelien M, Forand NR, Pugh N, Lindefors N, Lintvedt O, Zagorscak P, Carlbring P, Phillips R, Johansson R, Kessler RC, Brabyn S, Perini S, Rauch SL, Gilbody S, Moritz S, Berger T, Pop V, Kaldo V, Spek V & Forsell Y (2021) Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry, 78, 361-371. 
  34. Kataoka Y, Oide S, Arrie T, Tsujimoto Y & Furukawa TA (2021) The Methodological Quality Score of COVID-19 Systematic Reviews is Low, Except for Cochrane Reviews: A Meta-epidemiological Study. Annals of Clinical Epidemiology, 3, 46-55. 
  35. Kato Y, Matsuoka T, Eguchi Y, Iiboshi K, Koumi H, Nakamura K, Okabe K, Nakaaki S, Furukawa TA, Mimura M & Narumoto J (2021) Anxiety Impacts Consent Capacity to Treatment in Alzheimer's Disease. Frontiers in Psychology, 12, 685430. https://www.ncbi.nlm.nih.gov/pubmed/34194376 
  36. Katsura M, Kuriyama A, Tada M, Tsujimoto Y, Luo Y, Yamamoto K, So R, Aga M, Matsushima K, Fukuma S & Furukawa TA (2021) High variability in results and methodological quality among overlapping systematic reviews on the same topics in surgery: a meta-epidemiological study. British Journal of Surgery, 108, 1521-1529. https://www.ncbi.nlm.nih.gov/pubmed/34791075 
  37. Kimachi M, Onishi A, Tajika A, Kimachi K & Furukawa TA (2021) Systematic differences in effect estimates between observational studies and randomized control trials in meta-analyses in nephrology. Scientifi  Reports, 11, 6088. https://www.ncbi.nlm.nih.gov/pubmed/33731727 
  38. Kumagai N, Tajika A, Hasegawa A, Kawanishi N, Fujita H, Tsujino N, Jinnin R, Uchida M, Okamoto Y, Akechi T & Furukawa TA (2021) Assessing recurrence of depression using a zero-inflated negative binomial model: A secondary analysis of lifelog data. Psychiatry Research, 300, 113919. https://www.ncbi.nlm.nih.gov/pubmed/33864960 
  39. Leucht S, Cipriani A, Furukawa TA, Peter N, Tonia T, Papakonstantinou T, Holloway A & Salanti G (2021) A living meta-ecological study of the consequences of the COVID-19 pandemic on mental health. European Archives of Psychiatry and Clinical Neuroscience, 271, 219-221. https://www.ncbi.nlm.nih.gov/pubmed/33675417 
  40. Luo Y, Chaimani A, Furukawa TA, Kataoka Y, Ogawa Y, Cipriani A & Salanti G (2021) Visualizing the evolution of evidence: Cumulative network meta-analyses of new generation antidepressants in the last 40 years. Research Synthesis Methods, 12, 74-85. https://www.ncbi.nlm.nih.gov/pubmed/32352639 
  41. Luo Y, Ostinelli EG, Sahker E, Chaimani A, Kataoka Y, Ogawa Y, Cipriani A, Salanti G & Furukawa TA (2021) Antidepressant prescriptions have not fully reflected evolving evidence from cumulative network meta-analyses and guideline recommendations. Journal of Clinical Epidemiology, 133, 14-23. https://www.ncbi.nlm.nih.gov/pubmed/33359320 
  42. Maslej MM, Furukawa TA, Cipriani A, Andrews PW, Sanches M, Tomlinson A, Volkmann C, McCutcheon RA, Howes O, Guo X & Mulsant BH (2021) Individual Differences in Response to Antidepressants: A Meta-analysis of Placebo-Controlled Randomized Clinical Trials. JAMA Psychiatry, 78, 490-497. 
  43. Michopoulos I, Furukawa TA, Noma H, Kishimoto S, Onishi A, Ostinelli EG, Ciharova M, Miguel C, Karyotaki E & Cuijpers P (2021) Different control conditions can produce different effect estimates in psychotherapy trials for depression. Journal of Clinical Epidemiology, 132, 59-70. https://www.ncbi.nlm.nih.gov/pubmed/33338564 
  44. Miklowitz DJ, Efthimiou O, Furukawa TA, Scott J, McLaren R, Geddes JR & Cipriani A (2021) Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry, 78, 141-150. 
  45. Miklowitz DJ, Furukawa TA & Cipriani A (2021) Interpreting the Findings of a Meta-analysis of Psychosocial Interventions in Bipolar Disorder. JAMA Psychiatry, 78, 448-449.  
  46. Miyashita M, Yamasaki S, Ando S, Suzuki K, Toriumi K, Horiuchi Y, Yoshikawa A, Imai A, Nagase Y, Miyano Y, Inoue T, Endo K, Morimoto Y, Morita M, Kiyono T, Usami S, Okazaki Y, Furukawa TA, Hiraiwa-Hasegawa M, Itokawa M, Kasai K, Nishida A & Arai M (2021) Fingertip advanced glycation end products and psychotic symptoms among adolescents. NPJ Schizophrenia, 7, 37. 
  47. Nakagome K, Yokoi Y, Nakagawa A, Tani M, Nishioka G, Yoshimura N, Furukawa TA, Watanabe K, Mimura M, Iwanami A & Abe T (2021) Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. Journal of Affective Disorders, 282, 1011-1020. https://www.ncbi.nlm.nih.gov/pubmed/33601673 
  48. Nathwani G, Shoaib A, Shafi A, Furukawa TA & Huy NT (2021) Impact of COVID-2019 on school attendance problems. Journal of Global Health, 11, 03084. 
  49. Nikolakopoulou A, Mavridis D, Chiocchia V, Papakonstantinou T, Furukawa TA & Salanti G (2021) Network meta-analysis results against a fictional treatment of average performance: Treatment effects and ranking metric. Research Synthesis Methods, 12, 161-175. https://www.ncbi.nlm.nih.gov/pubmed/33070439 
  50. Nishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA, Sakai Y & Watanabe N (2021) Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews, 9, Cd012998.  
  51. Noma H, Shinozaki T, Iba K, Teramukai S & Furukawa TA (2021) Confidence intervals of prediction accuracy measures for multivariable prediction models based on the bootstrap-based optimism correction methods. Statistics in Medicine, 40, 5691-5701. https://www.ncbi.nlm.nih.gov/pubmed/34302372 
  52. Ostinelli EG, Zangani C, Giordano B, Maestri D, Gambini O, D'Agostino A, Furukawa TA & Purgato M (2021) Depressive symptoms and depression in individuals with Internet Gaming Disorder: a systematic review and meta-analysis. Journal of Affective Disorders, 136-142. 
  53. Petropoulou M, Efthimiou O, Rucker G, Schwarzer G, Furukawa TA, Pompoli A, Koek HL, Del Giovane C, Rodondi N & Mavridis D (2021) A review of methods for addressing components of interventions in meta-analysis. PLoS ONE, 16, e0246631. https://www.ncbi.nlm.nih.gov/pubmed/33556155 
  54. Sakata M, Toyomoto R, Yoshida K, Luo Y, Nakagami Y, Aoki S, Irie T, Sakano Y, Suga H, Sumi M, Muto T, Shiraishi N, Sahker E, Uwatoko T & Furukawa TA (2021) Development and validation of the Cognitive Behavioural Therapy Skills Scale among college students. Evidence-Based Mental Health, 24, 70-76. 
  55. Salanti G, Cipriani A, Furukawa TA, Peter N, Tonia T, Papakonstantinou T, Holloway A & Leucht S (2021) An efficient way to assess the effect of COVID-19 on mental health in the general population. Lancet Psychiatry, 8, e14-e15.  
  56. Sato H, Nakaaki S, Sato J, Shikimoto R, Furukawa TA, Mimura M & Akechi T (2021) Caregiver self-efficacy and associated factors among caregivers of patients with dementia with Lewy bodies and caregivers of patients with Alzheimer's disease. Psychogeriatrics, 21, 783-794. https://www.ncbi.nlm.nih.gov/pubmed/34216184 
  57. Schramm E, Rapee R & Furukawa TA (2021) Time for a paradigm shift for psychotherapies? Evidence-Based Mental Health, 24, 1.  
  58. Seo M, Furukawa TA, Veroniki AA, Pillinger T, Tomlinson A, Salanti G, Cipriani A & Efthimiou O (2021) The Kilim plot: A tool for visualizing network meta-analysis results for multiple outcomes. Research Synthesis Methods, 12, 86-95. 
  59. Tomitaka S & Furukawa TA (2021) The GAD-7 and the PHQ-8 exhibit the same mathematical pattern of item responses in the general population: analysis of data from the National Health Interview Survey. BMC Psychology, 9, 149. https://www.ncbi.nlm.nih.gov/pubmed/34556185 
  60. Tomitaka S & Furukawa TA (2021) Mathematical pattern of Kessler psychological distress distribution in the general population of the U.S. and Japan. BMC Psychiatry, 21, 188. https://www.ncbi.nlm.nih.gov/pubmed/33838666 
  61. Tsujimoto Y, Tsutsumi Y, Kataoka Y, Banno M & Furukawa TA (2021) Around ten percent of most recent Cochrane reviews included outcomes in their literature search strategy and were associated with potentially exaggerated results: A research-on-research study. Journal of Clinical Epidemiology, 141, 74-81. https://www.ncbi.nlm.nih.gov/pubmed/34474114 
  62. Wang Y, Devji T, Qasim A, Hao Q, Wong V, Bhatt M, Prasad M, Wang Y, Noori A, Xiao Y, Ghadimi M, Lozano LEC, Phillips MR, Carrasco-Labra A, King M, Terluin B, Terwee CB, Walsh M, Furukawa TA & Guyatt GH (2021) A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes. Journal of Clinical Epidemiology, 142, 144-151. https://www.ncbi.nlm.nih.gov/pubmed/34752937 
  63. Wiersma J, Klein P, Schramm E, Furukawa T & Favorite T (2021) Editorial: CBASP in the Treatment of Persistent Depressive Disorder. Frontiers in Psychiatry, 12. 
  64. Zhou X, Teng T, Del Giovane C, Furukawa TA, Weisz JR, Cipriani A & Xie P (2021) Treatment of depression in children and adolescents – Authors' reply   Lancet Psychiatry, 8, 97-98. 

2020

  1. Akechi T, Sugishita K, Chino B, Itoh K, Ikeda Y, Shimodera S, Yonemoto N, Miki K, Ogawa Y, Takeshima N, Kato T & Furukawa TA (2020) Whose depression deteriorates during acute phase antidepressant treatment? Journal of Affective Disorders, 260, 342-348.
  2. Bighelli I, Rodolico A, Pitschel-Walz G, Hansen WP, Barbui C, Furukawa TA, Salanti G & Leucht S (2020) Psychosocial treatments for relapse prevention in schizophrenia: Study protocol for a systematic review and network meta-analysis of randomised evidence. BMJ Open, 10, e035073.
  3. Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA & Kieling C (2020) The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: A systematic review and meta-analysis. European Neuropsychopharmacology, 33, 139-145.
  4. Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A & Furukawa TA (2020) A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19, 92-107.
  5. Devji T, Carrasco-Labra A, Qasim A, Phillips M, Johnston BC, Devasenapathy N, Zeraatkar D, Bhatt M, Jin X, Brignardello-Petersen R, Urquhart O, Foroutan F, Schandelmaier S, Pardo-Hernandez H, Vernooij RW, Huang H, Rizwan Y, Siemieniuk R, Lytvyn L, Patrick DL, Ebrahim S, Furukawa T, Nesrallah G, Schunemann HJ, Bhandari M, Thabane L & Guyatt GH (2020) Evaluating the credibility of anchor based estimates of minimal important differences for patient reported outcomes: Instrument development and reliability study. BMJ, 369, m1714. 
  6. Fodor LA, Georgescu R, Cuijpers P, Szamoskozi Ş, David D, Furukawa TA & Cristea IA (2020) Efficacy of cognitive bias modification interventions in anxiety and depressive disorders: A systematic review and network meta-analysis. Lancet Psychiatry, 7, 506-514.
  7. Funada S, Tabara Y, Setoh K, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, Watanabe N, Furukawa TA, Matsuda F & Ogawa O (2020) Reply by authors. Journal of Urology, 204, 1002.
  8. Funada S, Watanabe N, Goto T, Negoro H, Akamatsu S, Ueno K, Uozumi R, Ichioka K, Segawa T, Akechi T, Furukawa TA & Ogawa O (2020) Cognitive behavioral therapy for overactive bladder in women: Study protocol for a randomized controlled trial. BMC Urology, 20, 129.
  9. Funada S, Tabara Y, Setoh K, Negoro H, Akamatsu S, Yoshino T, Yoshimura K, Watanabe N, Furukawa TA, Matsuda F & Ogawa O (2020) Impact of nocturia on mortality: The nagahama study. Journal of Urology, 204, 996-1002.
  10. Furukawa TA (2020) Adolescent depression: From symptoms to individualised treatment? Lancet Psychiatry, 7, 295-296.
  11. Furukawa TA, Salanti G, Cowen PJ, Leucht S & Cipriani A (2020) No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: Systematic review. Acta Psychiatrica Scandinavica, 141, 401-409.
  12. Furukawa TA, Debray TPA, Akechi T, Yamada M, Kato T, Seo M & Efthimiou O (2020) Can personalized treatment prediction improve the outcomes, compared with the group average approach, in a randomized trial? Developing and validating a multivariable prediction model in a pragmatic megatrial of acute treatment for major depression. Journal of Affective Disorders, 274, 690-697.
  13. Furukawa TA (2020) Measuring clinical importance in a trial of interventions for mixed urinary incontinence. JAMA, 323, 479.
  14. Goto S, Sakamoto T, Ganeko R, Hida K, Furukawa TA & Sakai Y (2020) Subcuticular sutures for skin closure in non-obstetric surgery. Cochrane Database of Systematic Reviews, Art. No.: CD012124.
  15. Guaiana G, Barbui C, Meader N, Davies SJ, Furukawa TA, Imai H, Dias S, Caldwell DM, Kosters M, Tajika A, Bighelli I, Pompoli A & Cipriani A (2020) Pharmacological treatments in panic disorder in adults: A network meta-analysis (protocol). Cochrane Database of Systematic Reviews, CD012729.
  16. Hoshino N, Takada T, Hida K, Hasegawa S, Furukawa TA & Sakai Y (2020) Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery. Cochrane Database of Systematic Reviews, 3, CD012271.
  17. Imai H, Takamatsu T, Mitsuya H, Yoshizawa H, Mitsuya H & Furukawa TA (2020) The characteristics and social functioning of pathological social withdrawal, "hikikomori," in a secondary care setting: A one-year cohort study. BMC Psychiatry, 20, 352.
  18. Imai H, Yamada M, Inagaki M, Watanabe N, Chino B, Mantani A & Furukawa TA (2020) Behavioral Activation Contributed to the Total Reduction of Depression Symptoms in the Smartphone-based Cognitive Behavioral Therapy: A Secondary Analysis of a Randomized, Controlled Trial. Innov Clin Neurosci, 17, 21-25.
  19. Imai H, Furukawa TA, Hayashi SU, Goto A, Izumi K, Hayashino Y & Noda M (2020) Risk perception, self-efficacy, trust for physician, depression, and behavior modification in diabetic patients. J Health Psychol, 25, 350-360.
  20. Iwakami N, Nagai T, Furukawa TA, Tajika A, Onishi A, Nishimura K, Ogata S, Nakai M, Takegami M, Nakano H, Kawasaki Y, Alba AC, Guyatt GH, Shiraishi Y, Kohsaka S, Kohno T, Goda A, Mizuno A, Yoshikawa T & Anzai T (2020) Optimal sampling in derivation studies was associated with improved discrimination in external validation for heart failure prognostic models. Journal of Clinical Epidemiology, 121, 71-80.
  21. Iwakami N, Aiba T, Kamakura S, Takaki H, Furukawa TA, Sato T, Sun W, Shishido T, Nishimura K, Yamada-Inoue Y, Nagase S, Shimizu W, Yasuda S, Sugimachi M & Kusano K (2020) Identification of malignant early repolarization pattern by late qrs activity in high-resolution magnetocardiography. Annals of Noninvasive Electrocardiology, 25, e12741.
  22. Karageorgiou V, Furukawa TA, Tsigkaropoulou E, Karavia A, Gournellis R, Soureti A, Bellos I, Douzenis A & Michopoulos I (2020) Adipokines in anorexia nervosa: A systematic review and meta-analysis. Psychoneuroendocrinology, 112, 104485.
  23. Kataoka Y, Luo Y, Chaimani A, Onishi A, Kimachi M, Tsujimoto Y, Murad MH, Li T, Cipriani A & Furukawa TA (2020) Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: A meta-epidemiological study. Arch Osteoporos, 15, 21.
  24. Kataoka Y, Oide S, Ariie T, Tsujimoto Y & Furukawa TA (2020) The methodological quality of covid-19 systematic reviews is low, except for cochrane reviews: A meta-epidemiological study. medRxiv, 2020.2008.2028.20184077.
  25. Kataoka Y, Taito S, Yamamoto-Kataoka S, Tsujimoto Y, Yamazaki H & Furukawa TA (2020) Background styles in systematic review articles are not related to the publication in high-impact-factor journals: A meta-epidemiological study. Medicine, 99, e23801.
  26. Kataoka Y, Oide S, Ariie T, Tsujimoto Y & Furukawa TA (2020) Covid-19 randomized controlled trials in medrxiv and pubmed. Eur J Intern Med, 81, 97-99.
  27. Kikuchi S, Oe Y, Sasaki Y, Ishii H, Ito Y, Horikoshi M, Sozu T, Seno H & Furukawa TA (2020) Group cognitive behavioural therapy (gcbt) versus treatment as usual (tau) in the treatment of irritable bowel syndrome (ibs): A study protocol for a randomized controlled trial. BMC Gastroenterology, 20, 29.
  28. Levine SZ, Yoshida K, Goldberg Y, Samara M, Cipriani A, Efthimiou O, Iwatsubo T, Leucht S & Furukawa TA (2020) Linking the mini-mental state examination, the alzheimer’s disease assessment scale–cognitive subscale and the severe impairment battery: Evidence from individual participant data from five randomised clinical trials of donepezil. Evidence Based Mental Health.
  29. Luo Y, Kataoka Y, Ostinelli EG, Cipriani A & Furukawa TA (2020) National prescription patterns of antidepressants in the treatment of adults with major depression in the us between 1996 and 2015. Frontiers in Psychiatry, 11, 35.
  30. Luo Y, Funada S, Yoshioka T & Furukawa TA (2020) Challenges in systematic reviews that include observational studies: Comment on the article by karmacharya et al. Arthritis Rheumatol, 72, 2163-2164.
  31. Luo Y, Chalkou K, Yamada R, Funada S, Salanti G & Furukawa TA (2020) Predicting the treatment response of certolizumab for individual adult patients with rheumatoid arthritis: Protocol for an individual participant data meta-analysis. Syst Rev, 9, 140.
  32. Maruo K, Furukawa TA, Noma H, Imai H, Ikeda K & Yamawaki S (2020) Qualitative treatment-subgroup interactions in the antidepressant treatment of major depression: Application of quint to individual participant data from seven placebo-controlled randomized controlled trials. Personalized Medicine in Psychiatry, 21-22.
  33. Matsushima Y, Noma H, Yamada T & Furukawa TA (2020) Influence diagnostics and outlier detection for meta-analysis of diagnostic test accuracy. Res Synth Methods, 11, 237-247.
  34. Noma H, Gosho M, Ishii R, Oba K & Furukawa TA (2020) Outlier detection and influence diagnostics in network meta-analysis. Res Synth Methods, 11, 891-902.
  35. Noma H, Nagashima K & Furukawa TA (2020) Permutation inference methods for multivariate meta-analysis. Biometrics, 76, 337-347.
  36. Ogawa S, Imai R, Suzuki M, Furukawa TA & Akechi T (2020) The relationship between symptoms and social functioning over the course of cognitive behavioral therapy for social anxiety disorder. Psychiatry J, 2020, 3186450.
  37. Papola D, Ostuzzi G, Gastaldon C, Purgato M, Del Giovane C, Pompoli A, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers P & Barbui C (2020) Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses. BMJ Open, 10.
  38. Sahker E, Sakata M, Toyomoto R, Hwang C, Yoshida K, Luo Y, Watanabe N & Furukawa TA (2020) Efficacy of brief intervention for drug misuse in primary care facilities: Systematic review and meta-analysis protocol. BMJ Open, 10, e036633.
  39. Schramm E, Klein DN, Elsaesser M, Furukawa TA & Domschke K (2020) Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications. Lancet Psychiatry, 7, 801-812.
  40. So R, Furukawa TA, Matsushita S, Baba T, Matsuzaki T, Furuno S, Okada H & Higuchi S (2020) Unguided chatbot-delivered cognitive behavioural intervention for problem gamblers through messaging app: A randomised controlled trial. Journal of Gambling Studies, 36, 1391-1407.
  41. Sugimoto N, Nishida A, Ando S, Usami S, Toriyama R, Morimoto Y, Koike S, Yamasaki S, Kanata S, Fujikawa S, Furukawa TA, Sasaki T, Hiraiwa-Hasegawa M & Kasai K (2020) Use of social networking sites and desire for slimness among 10-year-old girls and boys: A population-based birth cohort study. International Journal of Eating Disorders, 53, 288-295.
  42. Takeshima N, Ishiwata K, Sozu T & Furukawa TA (2020) Primary endpoints in current phase ii/iii trials for alzheimer disease: A systematic survey of trials registered at clinicaltrials.gov. Alzheimer Disease and Associated Disorders, 34, 97-100.
  43. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2020) Age-related changes in item responses to the patient health questionnaire-9: Evidence from the national health and nutrition examination survey. Front Psychiatry, 11, 723.
  44. Tomlinson A, Furukawa TA, Efthimiou O, Salanti G, De Crescenzo F, Singh I & Cipriani A (2020) Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (petrushka): Rationale and protocol. Evidence-Based Mental Health, 23, 52-56.
  45. Tsujimoto Y, Fujii T, Onishi A, Omae K, Luo Y, Imai H, Takahashi S, Itaya T, Pinson C, Nevitt SJ & Furukawa TA (2020) No consistent evidence of data availability bias existed in recent individual participant data meta-analyses: A meta-epidemiological study. Journal of Clinical Epidemiology, 118, 107-114.e105.
  46. Watanabe N, Maruo K, Imai H, Ikeda K, Yamawaki S & Furukawa TA (2020) Predicting antidepressant response through early improvement of individual symptoms of depression incorporating baseline characteristics of patients: An individual patient data meta-analysis. Journal of Psychiatric Research, 125, 85-90.
  47. Yamada T, Nakaaki S, Sato J, Sato H, Shikimoto R, Furukawa TA, Mimura M & Akechi T (2020) Factor structure of the japanese version of the quality of life in alzheimer's disease scale (qol-ad). Psychogeriatrics, 20, 79-86.
  48. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A & Xie P (2020) Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: A systematic review and network meta-analysis. Lancet Psychiatry, 7, 581-601.

2019

  1. Akechi T, Kato T, Watanabe N, Tanaka S, Furukawa TA & for the SUN(^_^)D Investigators (2019) Predictors of hypomanic and/or manic switch among patients who initially diagnosed unipolar major depression during acute phase antidepressants treatment. Psychiatry and Clinical Neurosciences, 73, 90-91.
  2. Akechi T, Kato T, Fujise N, Yonemoto N, Tajika A & Furukawa TA (2019) Why some depressive patients perform suicidal acts and others do not. Psychiatry and Clinical Neurosciences, 73, 660-661.
  3. Akechi T, Mantani A, Kurata K, Hirota S, Shimodera S, Yamada M, Inagaki M, Watanabe N, Kato T & Furukawa TA (2019) Predicting relapse in major depression after successful initial pharmacological treatment. Journal of Affective Disorders, 250, 108-113.
  4. Ando S, Nishida A, Yamasaki S, Koike S, Morimoto Y, Hoshino A, Kanata S, Fujikawa S, Endo K, Usami S, Furukawa TA, Hiraiwa-Hasegawa M & Kasai K (2019) Cohort Profile: The Tokyo Teen Cohort study (TTC). International Journal of Epidemiology, 48, 1414-1414g.
  5. Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M, Bighelli I, Davies JC, Furukawa TA & Koesters M (2019) Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews, Art. No.: CD010677.
  6. Cuijpers P, Noma H, Karyotaki E, Cipriani A & Furukawa TA (2019) Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: A network meta-analysis. JAMA Psychiatry, 76, 700-707.
  7. Dumas-Mallet E, Tajika A, Smith A, Boraud T, Furukawa TA & Gonon F (2019) Do newspapers preferentially cover biomedical studies involving national scientists? Public Underst Sci, 28, 191-200.
  8. Fujii T, Belletti A, Carr A, Furukawa TA, Luethi N, Putzu A, Sartini C, Salanti G, Tsujimoto Y, Udy AA, Young PJ & Bellomo R (2019) Vitamin C therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis. BMJ Open, 9, e033458.
  9. Furukawa TA, Kato T, Shinagawa Y, Miki K, Fujita H, Tsujino N, Kondo M, Inagaki M & Yamada M (2019) Prediction of remission in pharmacotherapy of untreated major depression: development and validation of multivariable prediction models. Psychological Medicine, 49, 2405–2413.
  10. Furukawa TA, Karyotaki E, Suganuma A, Pompoli A, Ostinelli EG, Cipriani A, Cuijpers P & Efthimiou O (2019) Dismantling, personalising and optimising internet cognitive-behavioural therapy for depression: a study protocol for individual participant data component network meta-analysis. BMJ Open, 8, e026137.
  11. Furukawa TA, Reijnders M, Kishimoto S, Sakata M, DeRubeis RJ, Dimidjian S, Dozois DJA, Hegerl U, Hollon SD, Jarrett RB, Lesperance F, Segal ZV, Mohr DC, Simons AD, Quilty LC, Reynolds CF, Gentili C, Leucht S, Engel RR & Cuijpers P (2019) Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking. Epidemiol Psychiatr Sci, 1-13.
  12. Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M & Salanti G (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry, 6, 601-609.
  13. Furukawa TA (2019) Baseline severity and efficacy of antidepressants: into the third generation of research. Lancet Psychiatry, 6, 715-716.
  14. Furukawa TA, Cowen PJ, Salanti G, Leucht S, Egger M & Cipriani A (2019) Optimal dosing of antidepressant drugs - Authors' reply. Lancet Psychiatry, 6, 806-807.
  15. Furukawa TA (2019) An epidemic or a plague of common mental disorders? Acta Psychiatrica Scandinavica, 140, 391-392.
  16. Furukawa TA & Kessler RC (2019) Why has prevalence of mental disorders not decreased as treatment has increased? Australian and New Zealand Journal of Psychiatry, 53, 1143-1144.
  17. Harrer M, Cuijpers P, Furukawa TA & Ebert DD (2019) Doing Meta-Analysis in R: A Hands-on Guide.
  18. Iijima Y, Okumura Y, Yamasaki S, Ando S, Nakanishi M, Koike S, Endo K, Morimoto Y, Kanata S, Fujikawa S, Yamamoto Y, Furukawa TA, Hiraiwa-Hasegawa M, Kasai K & Nishida A (2019) Response inhibition and anxiety in adolescents: Results from a population-based community sample. Journal of Affective Disorders, 246, 89-95.
  19. Imai F, Momino K, Katsuki F, Horikoshi M, Furukawa TA, Kondo N, Toyama T, Yamaguchi T & Akechi T (2019) Smartphone problem-solving therapy to reduce fear of cancer recurrence among breast cancer survivors: an open single-arm pilot study. Japanese Journal of Clinical Oncology, 49, 537-544.
  20. Imai H, Takeshima N, Hayasaka Y, Yonemoto N, Ogawa Y, Tajika A, Fujita H, Kato T & Furukawa TA (2019) Association between patients' feedback comments and depressive mood, satisfaction, homework conducted, and dropouts during self-guided smartphone cognitive behavioral therapy. Psychiatry and Clinical Neurosciences, 73, 349-350.
  21. Inoue K, Kataoka SY, Kawano S, Furukawa TA, Lois N & Watanabe N (2019) Fenofibrate for diabetic retinopathy [Protocol]. Cochrane Database of Systematic Reviews, Art. No.: CD013318.
  22. Karyotaki E, Furukawa TA, Efthimiou O, Riper H & Cuijpers P (2019) Guided or self-guided internet-based cognitive-behavioural therapy (iCBT) for depression? Study protocol of an individual participant data network meta-analysis. BMJ Open, 9, e026820.
  23. Kumagai N, Tajika A, Hasegawa A, Kawanishi N, Horikoshi M, Shimodera S, Kurata Ki, Chino B & Furukawa TA (2019) Predicting recurrence of depression using lifelog data: an explanatory feasibility study with a panel VAR approach. BMC Psychiatry, 19.
  24. Matsushima Y, Noma H, Yamada T & Furukawa TA (2019) Influence diagnostics and outlier detection for meta-analysis of diagnostic test accuracy. Res Synth Methods. Nagashima K, Noma H & Furukawa TA (2019) Prediction intervals for random-effects meta-analysis: A confidence distribution approach. Statistical Methods in Medical Research, 28, 1689-1702.
  25. Nakanishi M, Yamasaki S, Endo K, Ando S, Morimoto Y, Fujikawa S, Kanata S, Takahashi Y, Furukawa TA, Richards M, Hiraiwa-Hasegawa M, Kasai K & Nishida A (2019) The association between role model presence and self-regulation in early adolescence: A cross-sectional study. PLoS ONE, 14.
  26. Noma H, Maruo K, Gosho M, Levine SZ, Goldberg Y, Leucht S & Furukawa TA (2019) Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. BMC Medical Research Methodology, 19, 33.
  27. Noma H, Furukawa TA, Maruo K, Imai H, Shinohara K, Tanaka S, Ikeda K, Yamawaki S & Cipriani A (2019) Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. Journal of Affective Disorders, 250, 419-424.
  28. Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D & Furukawa TA (2019) Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database of Systematic Reviews, 6, Cd001026.
  29. Omae K, Kataoka Y, Tsujimoto Y, Tsutsumi Y, Yamamoto Y, Fukuhara S & Furukawa TA (2019) Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation. BMC Cancer, 19, 998.
  30. Ostinelli EG, D'Agostino A, Shokraneh F, Salanti G & Furukawa TA (2019) Acute interventions for aggression and agitation in psychosis: study protocol for a systematic review and network meta-analysis. BMJ Open, 9, e032726.
  31. Schneider-Thoma J, Efthimiou O, Bighelli I, Dorries C, Huhn M, Krause M, Reichelt L, Roder H, Furukawa TA, Davis JM & Leucht S (2019) Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry, 6, 753-765.
  32. Seki T, Aki M, Kawashima H, Miki T, Tanaka S, Kawakami K & Furukawa TA (2019) Electronic health record nested pragmatic randomized controlled trial of a reminder system for serum lithium level monitoring in patients with mood disorder: KONOTORI study protocol. Trials, 20, 706.
  33. Shinohara K, Tanaka S, Imai H, Noma H, Maruo K, Cipriani A, Yamawaki S & Furukawa TA (2019) Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data. Evidence-Based Mental Health, 22, 10-16.
  34. Shinohara K, Efthimiou O, Ostinelli EG, Tomlinson A, Geddes JR, Nierenberg AA, Ruhe HG, Furukawa TA & Cipriani A (2019) Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and networkmeta-analysis. BMJ Open, 9.
  35. So R, Matsushita S, Kishimoto S & Furukawa TA (2019) Development and validation of the Japanese version of the problem gambling severity index. Addictive Behaviors, 98, 105987.
  36. Tada M, Azuma H, Yamada N, Kano KI, Nagai H, Maeda S, Ishida H, Aoyama T, Okada R, Kawano T, Kobuchi T, Uzui H, Matano H, Iwasaki H, Maeno K, Shimada Y, Yoshida H, Ando M, Murakami Y, Iwakami N, Kishimoto S, Iwami T, Tada H, Chapman A, Mills N, Hayashi H, Furukawa TA & Watanabe N (2019) A comprehensive validation of very early rule-out strategies for non-ST-segment elevation myocardial infarction in emergency departments: protocol for a multicentre prospective cohort study. BMJ Open, 9, e026985.
  37. Tada M, Matsumoto T, Takeda C, Yamada N, Furukawa TA & Watanabe N (2019) Ultrasound guidance versus landmark method for peripheral venous cannulation in adults [Protocol]. Cochrane Database of Systematic Reviews, 9, Art. No.:CD013434.
  38. Tajika A, Furukawa TA, Inagaki M, Kato T, Mantani A, Kurata K, Ogawa Y, Takeshima N, Hayasaka Y, Noma H & Maruo K (2019) Trajectory of criterion symptoms of major depression under newly started antidepressant treatment: sleep disturbances and anergia linger on while suicidal ideas and psychomotor symptoms disappear early. Acta Psychiatrica Scandinavica, 140, 532-540.
  39. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2019) Further evidence that item responses on the Kessler Psychological Distress Scale exhibit the characteristic pattern in the general population. Heliyon, 5.
  40. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2019) Distribution of psychological distress is stable in recent decades and follows an exponential pattern in the US population. Sci Rep, 9, 11982.
  41. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2019) Responses to depressive symptom items exhibit a common mathematical pattern across the European populations. Sci Rep, 9, 14923.
  42. Tomlinson A, Efthimiou O, Boaden K, New E, Mather S, Salanti G, Imai H, Ogawa Y, Tajika A, Kishimoto S, Kikuchi S, Chevance A, Furukawa TA & Cipriani A (2019) Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. Evidence-Based Mental Health, 22, 61-66.
  43. Tsujimoto Y, Aoki T, Shinohara K, So R, Suganuma AM, Kimachi M, Yamamoto Y & Furukawa TA (2019) Physician characteristics associated with proper assessment of overstated conclusions in research abstracts: A secondary analysis of a randomized controlled trial. PLoS ONE, 14, e0211206.
  44. Tsujimoto Y, Tsutsumi Y, Kataoka Y, Tsujimoto H, Yamamoto Y, Papola D, Guyatt GH, Fukuhara S & Furukawa TA (2019) Statistical significance did not affect time to publication in non-Cochrane systematic reviews: a metaepidemiological study. Journal of Clinical Epidemiology, 115, 25-34.
  45. Watanabe N, Horikoshi M, Shinmei I, Oe Y, Narisawa T, Kumachi M, Matsuoka Y, Hamazaki K & Furukawa TA (2019) Brief mindfulness-based stress management program for a better mental state in working populations - Happy Nurse Project: A randomized controlled trial(). Journal of Affective Disorders, 251, 186-194.
  46. Wong QJJ, Chen J, Gregory B, Baillie AJ, Nagata T, Furukawa TA, Kaiya H, Peters L & Rapee RM (2019) Measurement equivalence of the Social Interaction Anxiety Scale (SIAS) and Social Phobia Scale (SPS) across individuals with social anxiety disorder from Japanese and Australian sociocultural contexts. Journal of Affective Disorders, 243, 165-174.
  47. Yamamoto-Sasaki M, Yoshida S, Takeuchi M, Tanaka-Mizuno S, Ogawa Y, Furukawa TA & Kawakami K (2019) Association between antidepressant use during pregnancy and autism spectrum disorder in children: a retrospective cohort study based on Japanese claims data. Maternal Health, Neonatology and Perinatology, 5.
  48. Yamasaki S, Ando S, Richards M, Hatch SL, Koike S, Fujikawa S, Kanata S, Endo K, Morimoto Y, Arai M, Okado H, Usami S, Furukawa TA, Hiraiwa-Hasegawa M, Kasai K & Nishida A (2019) Maternal diabetes in early pregnancy, and psychotic experiences and depressive symptoms in 10-year-old offspring: A population-based birth cohort study. Schizophrenia Research, 206, 52-57.
  49. Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA & Watanabe N (2019) Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, Art. No.:CD012893.
  50. Zhou X, Zhang Y, Furukawa TA, Cuijpers P, Pu J, Weisz JR, Yang L, Hetrick SE, Del Giovane C, Cohen D, James AC, Yuan S, Whittington C, Jiang X, Teng T, Cipriani A & Xie P (2019) Different types and acceptability of psychotherapies for acute anxiety disorders in children and adolescents: A network meta-analysis. JAMA Psychiatry, 76, 41-50.

2018

  1. Akechi T, Yamaguchi T, Uchida M, Imai F, Momino K, Katsuki F, Sakurai N, Miyaji T, Horikoshi M, Furukawa TA, Iwata H & Uchitomi Y (2018) Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial. BMJ Open, 8, e024794.
  2. Ando S, Nishida A, Usami S, Koike S, Yamasaki S, Kanata S, Fujikawa S, Furukawa TA, Fukuda M, Sawyer SM, Hiraiwa-Hasegawa M & Kasai K (2018) Help-seeking intention for depression in early adolescents: Associated factors and sex differences. Journal of Affective Disorders, 238, 359-365.
  3. Bighelli I, Salanti G, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, Wallis S, Schwermann F, Pitschel-Walz G, Barbui C, Furukawa TA & Leucht S (2018) Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. World Psychiatry, 17, 316-329.
  4. Bighelli I, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, Wallis S, Schwermann F, Pitschel-Walz G, Barbui C, Furukawa TA & Leucht S (2018) Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. BMC Psychiatry, 18, 380.
  5. Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA & Barbui C (2018) Antidepressants versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews, 4, Cd010676.
  6. Bighelli I, Salanti G, Reitmeir C, Wallis S, Barbui C, Furukawa TA & Leucht S (2018) Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 8, e019280.
  7. Bonner A, Alexander PE, Brignardello-Petersen R, Furukawa TA, Siemieniuk RA, Zhang Y, Wiercioch W, Florez ID, Fei Y, Agarwal A, Yepes-Nunez JJ, Beyene J, Schunemann H & Guyatt GH (2018) Applying GRADE to a network meta-analysis of antidepressants led to more conservative conclusions. Journal of Clinical Epidemiology, 102, 87-98.
  8. Breilmann J, Furukawa TA, Becker T & Koesters M (2018) Differences in the placebo response in duloxetine and venlafaxine trials. Acta Psychiatrica Scandinavica, 137, 472-480.
  9. Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, Hazlewood GS, Alhazzani W, Mustafa RA, Murad MH, Puhan MA, Schunemann HJ & Guyatt GH (2018) Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. Journal of Clinical Epidemiology, 93, 36-44. (Brignardello-Petersen R, Bonner A, Alexander PE, Siemieniuk RA, Furukawa TA, Rochwerg B, Hazlewood GS, Alhazzani W, Mustafa RA, Murad MH, Puhan MA, Schunemann HJ & Guyatt GH (2018) Corrigendum to "Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis" [J Clin Epidemiol 2018;93:36-44]. Journal of Clinical Epidemiology, 98, 162.)
  10. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA & Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 391, 1357-1366.
  11. Cipriani A, Salanti G, Furukawa TA, Turner E, Ioannidis JPA & Geddes JR (2018) Network meta-analysis of antidepressants - Authors' reply. Lancet, 392, 1012-1013.
  12. Cipriani A, Salanti G, Furukawa TA, Egger M, Leucht S, Ruhe HG, Turner EH, Atkinson LZ, Chaimani A, Higgins JPT, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA & Geddes JR (2018) Antidepressants might work for people with major depression: where do we go from here? Lancet Psychiatry, 5, 461-463.
  13. Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, Vincent JL, Pasero D, Robert R, Ronco C & Bagshaw SM (2018) Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine, 44, 167-178. (Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, Vincent JL, Pasero D, Robert R, Ronco C & Bagshaw SM (2018) Correction to: Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Medicine, 44, 279-280.)
  14. Fujikawa S, Ando S, Nishida A, Usami S, Koike S, Yamasaki S, Morimoto Y, Toriyama R, Kanata S, Sugimoto N, Sasaki T, Furukawa TA, Hiraiwa-Hasegawa M & Kasai K (2018) Disciplinary slapping is associated with bullying involvement regardless of warm parenting in early adolescence. Journal of Adolescence, 68, 207-216.
  15. Furukawa TA, Horikoshi M, Fujita H, Tsujino N, Jinnin R, Kako Y, Ogawa S, Sato H, Kitagawa N, Shinagawa Y, Ikeda Y, Imai H, Tajika A, Ogawa Y, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M & Hasegawa A (2018) Cognitive and behavioral skills exercises completed by patients with major depression during smartphone cognitive behavioral therapy: Secondary analysis of a randomized controlled trial. JMIR Mental Health, 5, e4.
  16. Furukawa TA, Cipriani A, Leucht S, Atkinson LZ, Ogawa Y, Takeshima N, Hayasaka Y, Chaimani A & Salanti G (2018) Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evidence-Based Mental Health, 21, 1-3.
  17. Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S & Cipriani A (2018) Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatrica Scandinavica, 137, 450-458.
  18. Furukawa TA, Imai H, Horikoshi M, Shimodera S, Hiroe T, Funayama T & Akechi T (2018) Behavioral activation: Is it the expectation or achievement, of mastery or pleasure that contributes to improvement in depression? Journal of Affective Disorders, 238, 336-341.
  19. Furukawa TA, Efthimiou O, Weitz ES, Cipriani A, Keller MB, Kocsis JH, Klein DN, Michalak J, Salanti G, Cuijpers P & Schramm E (2018) Cognitive-Behavioral Analysis System of Psychotherapy, drug, or their combination for persistent depressive disorder: Personalizing the treatment choice using individual participant data network metaregression. Psychotherapy and Psychosomatics, 87, 140-153.
  20. Furukawa TA, Karyotaki E, Suganuma A, Pompoli A, Ostinelli EG, Cipriani A, Cuijpers P & Efthimiou O (2018) Dismantling, personalising and optimising internet cognitive-behavioral therapy for depression: A study protocol for individual participant data component network meta-analysis. BMJ Open, 8, e026137.
  21. Furukawa TA, Kato T, Akechi T, Shimodera S, Okada N, Yanai I, Ozaki K & Kinou K (2018) Dropouts in an antidepressant trial: How do they fare afterwards? Psychotherapy and Psychosomatics, 87, 380-382.
  22. Furukawa TA (2018) Choosing the optimum strategy for rTMS. Evidence-Based Mental Health, 21, 77-78.
  23. Hoshino N, Takada T, Hida K, Hasegawa S, Furukawa TA & Sakai Y (2018) Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery. Cochrane Database of Systematic Reviews, CD012271.
  24. Iijima Y, Okumura Y, Yamasaki S, Ando S, Nakanishi M, Koike S, Endo K, Morimoto Y, Kanata S, Fujikawa S, Yamamoto Y, Furukawa TA, Hiraiwa-Hasegawa M, Kasai K & Nishida A (2018) Response inhibition and anxiety in adolescents: Results from a population-based community sample. Journal of Affective Disorders, 246, 89-95.
  25. Imai H, Furukawa TA, Hayashi SU, Goto A, Izumi K, Hayashino Y & Noda M (2018) Risk perception, self-efficacy, trust for physician, depression, and behavior modification in diabetic patients. Journal of Health Psychology, 1359105317718057.
  26. Imamura K, Furukawa TA, Matsuyama Y, Shimazu A, Kuribayashi K, Kasai K & Kawakami N (2018) Differences in the Effect of Internet-Based Cognitive Behavioral Therapy for Improving Nonclinical Depressive Symptoms Among Workers by Time Preference: Randomized Controlled Trial. Journal of Medical Internet Research, 20, e10231.
  27. Iwakami N, Nagai T, Furukawa TA & Anzai T (2018) Response to letter regarding article by Formiga et al., "Utility of the Controlling Nutritional Status (CONUT) score in patients admitted due to acute heart failure". International Journal of Cardiology, 256, 25.
  28. Kataoka Y, Luo Y, Chaimani A, Onishi A, Kimachi M, Tsujimoto Y, Murad MH, Li T, Cipriani A & Furukawa TA (2018) Cumulative network-meta-analyses, practice guidelines and actual prescriptions of drug treatments for postmenopausal osteoporosis: A study protocol for cumulative network meta-analyses and meta-epidemiological study. BMJ Open, 8, e023218.
  29. Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K, Ikeda Y, Shinagawa Y, Kondo M, Okamoto Y, Fujita H, Suga M, Yasumoto S, Tsujino N, Inoue T, Fujise N, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M, Miki K, Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Shinohara K, Yonemoto N, Tanaka S, Zhou Q, Guyatt GH & for the SUN(^_^)D Investigators (2018) Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Medicine, 16, 103.
  30. Katsuki F, Takeuchi H, Inagaki T, Maeda T, Kubota Y, Shiraishi N, Tabuse H, Kato T, Yamada A, Watanabe N, Akechi T & Furukawa TA (2018) Brief multifamily Psychoeducation for family members of patients with chronic major depression: a randomized controlled trial. BMC Psychiatry, 18, 207.
  31. Kikuchi S, Naoki Y, Tajiri T & Watanabe N (2018) Proton pump inhibitors for chronic obstructive pulmonary disease [Protocol]. Cochrane Database of Systematic Reviews.
  32. Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, Gomaa H, Lee Y, Katsura M, Tada M, Hong BY, Cho SM, Hong PJ, Yu AM, Sivji Y, Toma A, Xie L, Tsoi L, Waligora M, Prasad M, Bhatnagar N, Thabane L, Brundage M, Guyatt G & Xie F (2018) Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: A systematic review and quantitative analysis. JAMA Internal Medicine, 178, 1586-1596.
  33. Leucht S, Levine SZ, Samara M, Cipriani A, Davis JM & Furukawa TA (2018) Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why? European Archives of Psychiatry and Clinical Neuroscience, 268, 621-623.
  34. Luo Y, Chaimani A, Kataoka Y, Ostinelli EG, Ogawa Y, Cipriani A, Salanti G & Furukawa TA (2018) Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study. BMJ Open, 8, e023222.
  35. Nikolakopoulou A, Mavridis D, Furukawa TA, Cipriani A, Tricco AC, Straus SE, Siontis GCM, Egger M & Salanti G (2018) Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study. BMJ, 360, k585.
  36. Nishizaki D, Ganeko R, Hoshino N, Hida K, Obama K, Furukawa TA, Sakai Y & Watanabe N (2018) Roux-en-Y versus Billroth-I reconstruction after distal gastrectomy for gastric cancer [Protocol]. Cochrane Database of Systematic Reviews, CD012998.
  37. Noma H, Nagashima K, Maruo K, Gosho M & Furukawa TA (2018) Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network meta-analysis. Statistics in Medicine, 37, 1178-1190.
  38. Ogawa Y, Takeshima N & Furukawa TA (2018) Maternal exposure to benzodiazepine and risk of preterm birth and low birth weight: A case-control study using a claims database in Japan. Asia Pacific Psychiatry, 10, e12309.
  39. Ogawa Y, Furukawa TA, Takeshima N, Hayasaka Y, Atkinson LZ, Tanaka S, Cipriani A & Salanti G (2018) Efficacy of antidepressants over placebo is similar in two-armed versus three-armed or more-armed randomized placebo-controlled trials. International Clinical Psychopharmacology, 33, 66-72.
  40. Pompoli A, Furukawa TA, Efthimiou O, Imai H, Tajika A & Salanti G (2018) Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. Psychological Medicine, 48, 1945-1953.
  41. Qin Z, Xie S, Mao Z, Liu Y, Wu J, Furukawa TA, Kwong JSW, Tian J & Liu Z (2018) Comparative efficacy and acceptability of antiepileptic drugs for classical trigeminal neuralgia: a Bayesian network meta-analysis protocol. BMJ Open, 8, e017392.
  42. Salanti G, Chaimani A, Furukawa TA, Higgins JPT, Ogawa Y, Cipriani A & Egger M (2018) Impact of placebo arms on outcomes in antidepressant trials: systematic review and meta-regression analysis. International Journal of Epidemiology, 47, 1454-1464.
  43. So R, Shinohara K, Aoki T, Tsujimoto Y, Suganuma AM & Furukawa TA (2018) Effect of recruitment methods on response rate in a web-based study for primary care physicians: Factorial randomized controlled trial. Journal of Medical Internet Research, 20, e28.
  44. Takagaki K, Okamoto Y, Jinnin R, Mori A, Nishiyama Y, Yamamura T, Yokoyama S, Shiota S, Okamoto Y, Miyake Y, Ogata A, Kunisato Y, Shimoda H, Kawakami N, Furukawa TA & Yamawaki S (2018) Enduring effects of a 5-week behavioral activation program for subthreshold depression among late adolescents: an exploratory randomized controlled trial. Neuropsychiatric Disease and Treatment, 14, 2633-2641.
  45. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2018) Stability of the Distribution of Patient Health Questionnaire-9 Scores Against Age in the General Population: Data From the National Health and Nutrition Examination Survey. Frontier in Psychiatry, 9, 390.
  46. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Ono Y & Furukawa TA (2018) Distribution of item responses and total item scores for the Center for Epidemiologic Studies Depression Scale (CES-D): Data from the Irish Longitudinal Study on Ageing (TILDA). PLoS ONE, 13, e0202607.
  47. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H, Ono Y & Furukawa TA (2018) Distributional patterns of item responses and total scores on the PHQ-9 in the general population: data from the National Health and Nutrition Examination Survey. BMC Psychiatry, 18, 108.
  48. Tong Z, Li F, Ogawa Y, Watanabe N & Furukawa TA (2018) Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study. BMC Medical Research Methodology, 18, 96.
  49. Uwatoko T, Luo Y, Sakata M, Kobayashi D, Sakagami Y, Takemoto K, Collins LM, Watkins E, Hollon SD, Wason J, Noma H, Horikoshi M, Kawamura T, Iwami T & Furukawa TA (2018) Healthy Campus Trial: a multiphase optimization strategy (MOST) fully factorial trial to optimize the smartphone cognitive behavioral therapy (CBT) app for mental health promotion among university students: study protocol for a randomized controlled trial. Trials, 19, 353.
  50. Watanabe N, Matsuoka Y, Kumachi M, Hamazaki K, Horikoshi M & Furukawa TA (2018) Omega-3 fatty acids for a better mental state in working populations - Happy Nurse Project: A 52-week randomized controlled trial. Journal of Psychiatric Research, 102, 72-80.
  51. Zhou X, Cipriani A, Furukawa TA, Cuijpers P, Zhang Y, Hetrick SE, Pu J, Yuan S, Del Giovane C & Xie P (2018) Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysis. BMJ Open, 8, e018357.

2017

  1. Ando S, Koike S, Shimodera S, Fujito R, Sawada K, Terao T, Furukawa TA, Sasaki T, Inoue S, Asukai N, Okazaki Y & Nishida A (2017) Lithium Levels in Tap Water and the Mental Health Problems of Adolescents: An Individual-Level Cross-Sectional Survey. Journal of Clinical Psychiatry, 78, e252-e256.
  2. Cipriani A, Furukawa TA, Atkinson LZ, Leucht S & Salanti G (2017) DSM-III-R change in definition might have affected placebo response to antidepressants - Authors' reply. Lancet Psychiatry, 4, 22-23.
  3. Cuijpers P, Huibers MJ & Furukawa TA (2017) The Need for Research on Treatments of Chronic Depression. JAMA Psychiatry, 74, 242-243.
  4. Furukawa TA, Weitz ES, Tanaka S, Hollon SD, Hofmann SG, Andersson G, Twisk J, DeRubeis RJ, Dimidjian S, Hegerl U, Mergl R, Jarrett RB, Vittengl JR, Watanabe N & Cuijpers P (2017) Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. British Journal of Psychiatry, 210, 190-196.
  5. Furukawa TA (2017) Evidence-Based Case Conference (10) Prognosis of delirium. Evidence-Based Mental Health, 20, 53-54.
  6. Guaiana G, Barbui C, Caldwell DM, Davies SJ, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A & Cipriani A (2017) Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis [Protocol]. Cochrane Database of Systematic Reviews, CD012729.
  7. Hashimoto K, Ogawa Y, Takeshima N & Furukawa TA (2017) Psychological and educational interventions for atopic dermatitis in adults: A systematic review and meta-analysis. Behaviour Change, 34, 48-65.
  8. Imai H & Furukawa TA (2017) No significant difference in long-term remission between psychological therapies and antidepressants in panic disorder. Evidence-Based Mental Health.
  9. Imai H, Takeshima N, Oda H, Chen P, Sawada E & Furukawa TA (2017) Choto-san versus placebo for patients with dementia: systematic review and meta-analysis. Psychogeriatrics, 17, 466-478.
  10. Ino K, Ogawa S, Kondo M, Imai R, Ii T, Furukawa TA & Akechi T (2017) Anxiety sensitivity as a predictor of broad dimensions of psychopathology after cognitive behavioral therapy for panic disorder. Neuropsychiatric Disease and Treatment, 13, 1835-1840.
  11. Itani O, Jike M, Watanabe N, Kaneita Y (2017) Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Medicine, 32, 246-256.
  12. Ito M, Horikoshi M, Resick PA, Katayanagi A, Miyamae M, Takagishi Y, Takebayashi Y, Kanie A, Hirabayashi N & Furukawa TA (2017) Study protocol for a randomised controlled trial of cognitive processing therapy for post-traumatic stress disorder among Japanese patients: the Safety, Power, Intimacy, Esteem, Trust (SPINET) study. BMJ Open, 7, e014292.
  13. Iwakami N, Nagai T, Furukawa TA, Sugano Y, Honda S, Okada A, Asaumi Y, Aiba T, Noguchi T, Kusano K, Ogawa H, Yasuda S & Anzai T (2017) Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. International Journal of Cardiology, 230, 529-536.
  14. Jinnin R, Okamoto Y, Takagaki K, Nishiyama Y, Yamamura T, Okamoto Y, Miyake Y, Takebayashi Y, Tanaka K, Sugiura Y, Shimoda H, Kawakami N, Furukawa TA & Yamawaki S (2017) Detailed course of depressive symptoms and risk for developing depression in late adolescents with subthreshold depression: cohort study. Neuropsychiatric Disease and Treatment, 13, 25-33.
  15. Katsura M, Kuriyama A, Tada M, Yamamoto K & Furukawa TA (2017) Redundant systematic reviews on the same topic in surgery: a study protocol for a meta-epidemiological investigation. BMJ Open, 7, e017411.
  16. Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S & Fukuhara S (2017) Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database of Systematic Reviews, 11, CD011373.
  17. Kochi K, Sato I, Nishiyama C, Tanaka-Mizuno S, Doi Y, Arai M, Fujii Y, Matsunaga T, Ogawa Y, Furukawa TA & Kawakami K (2017) Trends in antipsychotic prescriptions for Japanese outpatients during 2006-2012: a descriptive epidemiological study. Pharmacoepidemiol Drug Saf, 26, 642-656.
  18. Kusaka K, Shinohara K, Tada M, Watanabe N & Furukawa TA (2017) Concerns about selective outcome reporting. Journal of Clinical Oncology, 35, 688.
  19. Mantani A, Kato T, Furukawa TA, Horikoshi M, Imai H, Hiroe T, Chino B, Funayama T, Yonemoto N, Zhou Q & Kawanishi N (2017) Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. Journal of Medical Internet Research, 19, e373. (Mantani A, Kato T, Furukawa TA, Horikoshi M, Imai H, Hiroe T, Chino B, Funayama T, Yonemoto N, Zhou Q & Kawanishi N (2018) Correction: Smartphone Cognitive Behavioral Therapy as an Adjunct to Pharmacotherapy for Refractory Depression: Randomized Controlled Trial. Journal of Medical Internet Research, 20, e11702.)
  20. Morokuma Y, Endo K, Nishida A, Yamasaki S, Ando S, Morimoto Y, Nakanishi M, Okazaki Y, Furukawa TA, Morinobu S & Shimodera S (2017) Sex differences in auditory verbal hallucinations in early, middle and late adolescence: results from a survey of 17 451 Japanese students aged 12-18 years. BMJ Open, 7, e015239.
  21. Noma H, Tanaka S, Matsui S, Cipriani A & Furukawa TA (2017) Quantifying indirect evidence in network meta-analysis. Statistics in Medicine, 36, 917-927.
  22. Obbarius A, van Maasakkers L, Baer L, Clark DM, Crocker AG, de Beurs E, Emmelkamp PMG, Furukawa TA, Hedman-Lagerlof E, Kangas M, Langford L, Lesage A, Mwesigire DM, Nolte S, Patel V, Pilkonis PA, Pincus HA, Reis RA, Rojas G, Sherbourne C, Smithson D, Stowell C, Woolaway-Bickel K & Rose M (2017) Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM Depression and Anxiety Working Group. Quality of Life Research, 26, 3211-3225.
  23. Ogawa S, Kondo M, Ino K, Ii T, Imai R, Furukawa TA & Akechi T (2017) Fear of fear and broad dimensions of psychopathology over the course of cognitive behavioural therapy for panic disorder with agoraphobia in Japan. East Asian Archives of Psychiatry, 27, 150-155.
  24. Ogawa S, Imai R, Suzuki M, Furukawa TA & Akechi T (2017) The mechanisms underlying changes in broad dimensions of psychopathology during cognitive behavioural therapy for social anxiety disorder. Journal of Clinical Medicine Research, 9, 1019-1021.
  25. Ogawa S, Kondo M, Okazaki J, Imai R, Ino K, Furukawa TA & Akechi T (2017) The relationships between symptoms and quality of life over the course of cognitive-behavioral therapy for panic disorder in Japan. Asia Pacific Psychiatry, 9.
  26. Okuyama T, Akechi T, Mackenzie L & Furukawa TA (2017) Psychotherapy for depression among advanced, incurable cancer patients: A systematic review and meta-analysis. Cancer Treatment Reviews, 56, 16-27.
  27. Omae K, Tsujimoto Y, Honda M, Kondo T, Tanabe K, Fukuhara S & Furukawa TA (2017) Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Oncotarget, 8, 68890-68898.
  28. Ostuzzi G, Bighelli I, So R, Furukawa TA & Barbui C (2017) Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophrenia Research, 183, 10-21.
  29. Samara MT, Goldberg Y, Levine SZ, Furukawa TA, Geddes JR, Cipriani A, Davis JM & Leucht S (2017) Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry, 4, 859-867.
  30. Shinohara K, Aoki T, So R, Tsujimoto Y, Suganuma AM, Kise M & Furukawa TA (2017) Influence of overstated abstract conclusions on clinicians: a web-based randomised controlled trial. BMJ Open, 7, e018355.
  31. Shinohara K, Suganuma AM, Imai H, Takeshima N, Hayasaka Y & Furukawa TA (2017) Overstatements in abstract conclusions claiming effectiveness of interventions in psychiatry: A meta-epidemiological investigation. PLoS ONE, 12, e0184786.
  32. Song L, Yoshida S, Tanaka-Mizuno S, Ogawa Y, Furukawa TA & Kawakami K (2017) Association between eicosapentaenoic acid (EPA) medication intake and new onset of depression among patients with hyperlipidemia: a 3-year follow-up study. Journal of Nutrition & Intermediary Metabolism, 9, 12-16.
  33. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H, Ono Y & Furukawa TA (2017) Pattern analysis of total item score and item response of the Kessler Screening Scale for Psychological Distress (K6) in a nationally representative sample of US adults. PeerJ, 5, e2987.
  34. Tomitaka S, Furukawa TA, Kawasaki Y, Ide K, Akutagawa M & Ono Y (2017) Characteristic distribution of the total and individual item scores on the Kessler Screening Scale for Psychological Distress (K6) in US adults. BMC Psychiatry, 17, 290.
  35. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H, Yutaka O & Furukawa TA (2017) Item Response Patterns on the Patient Health Questionnaire-8 in a Nationally Representative Sample of US Adults. Frontiers inPsychiatry, 8, 251.
  36. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H & Furukawa TA (2017) Exponential distribution of total depressive symptom scores in relation to exponential latent trait and item threshold distributions: a simulation study. BMC Research Notes, 10, 614.
  37. Tsujimoto Y, Tsutsumi Y, Kataoka Y, Tsujimoto H, Yamamoto Y, Papola D, Guyatt GH, Fukuhara S & Furukawa TA (2017) Association between statistical significance and time to publication among systematic reviews: a study protocol for a meta-epidemiological investigation. BMJ Open, 7, e018856.
  38. Tsutsumi Y, Tsutsumi I, Tsujimoto Y, Takahashi s, Tsuchiya A, Miyakoshi C, Fukuma S & Furukawa TA (2017) Hyperbaric oxygen therapy for persistent post-concussion syndrome following mild traumatic brain injury [Protocol]. Cochrane Database of Systematic Reviews, Art. No.: CD012727.
  39. Yamada A, Suzuki M, Kyo M, Katsuki F, Shiraishi N, Watanabe N, Akechi T (2017) Group psychoeducational programs improve mood profiles in mothers of non-attendance school children. Neuropsychiatry (London), 7(5), 637-643.
  40. Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA & Watanabe N (2017) Certolizumab pegol for induction of remission in Crohn's disease [Protocol]. Cochrane Database of Systematic Reviews, 12, Art. No.: CD012893.
  41. Zhou X, Cipriani A, Zhang Y, Cuijpers P, Hetrick SE, Weisz JR, Pu J, Giovane CD, Furukawa TA, Barth J, Coghill D, Leucht S, Yang L, Ravindran AV & Xie P (2017) Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. BMJ Open, 7, e016608.

2016

  1. Barber S, Corsi M, Furukawa TA & Cipriani A (2016) Quality and impact of secondary information in promoting evidence-based clinical practice: a cross-sectional study about EBMH. Evidence-Based Mental Health, 19, 82-85.
  2. Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, Gualana G, Koesters M & Barbui C (2016) Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database of Systematic Reviews, 9, CD011567.
  3. De Crescenzo F, Foti F, Ciabattini M, Giovane DC, Watanabe N, Schepisi MS, Quested DJ, Cipriani A, Barbui C, Amato L (2016) Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis [Protocol]. Cochrane Database Systematic Reviews, 9, CD012364.
  4. Fujii T, Ganeko R, Kataoka Y, Featherstone R, Bagshaw SM & Furukawa TA (2016) Polymixin B-immobilized hemoperfusion and mortality in critically ill patients with sepsis/septic shock: Protocol for a systematic review and meta-analysis. BMJ Open, 6, e012908.
  5. Furukawa TA, Cipriani A, Atkinson LZ, Leucht S, Ogawa Y, Takeshima N, Hayasaka Y, Chaimani A & Salanti G (2016) Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry, 3, 1059-1066.
  6. Furukawa TA (2016) Evidence-Based Case Conference (9) Which psychotherapy for PTSD? Evidence-Based Mental Health, 19, 118-119.
  7. Honda M, Hiki N, Kinoshita T, Yabusaki H, Abe T, Nunobe S, Terada M, Matsuki A, Sunagawa H, Aizawa M, Healy MA, Iwasaki M & Furukawa TA (2016) Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage I Gastric Cancer: The LOC-1 Study. Annals of Surgery, 264, 214-222.
  8. Furukawa TA, Salanti G, Atkinson L, Leucht S, Ruhe E, Turner EH, Chaimani A, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Suganuma A, Watanabe N, Stockton S, Geddes J & Cipriani A (2016) Comparative efficacy and acceptability of first- and second-generation antidepressants in the acute treatment of major depression: Protocol for a network meta-analysis. BMJ Open, 6, e010919.
  9. Furukawa TA (2016) A guideline for whom? Epidemiology and Psychiatric Sciences, 25, 439-440.
  10. Furukawa TA, Schramm E, Weitz ES, Salanti G, Efthimiou O, Michalak J, Watanabe N, Cipriani A, Keller MB, Kocsis JH, Klein DN & Cuijpers P (2016) Cognitive-Behavioral Analysis System of Psychotherapy (CBASP), drug or their combination: Differential therapeutics for persistent depressive disorder: A study protocol of an individual participant data network meta-analysis. BMJ Open, 6, e011769.
  11. Furukawa TA (2016) Evidence-Based Case Conference (8) Diagnosing autism spectrum disorder (ASD) among adults. Evidence-Based Mental Health, 19, 46-48.
  12. Furukawa TA, Miura T, Chaimani A, Leucht S, Cipriani A, Noma H, Mitsuyasu H, Kanba S & Salanti G (2016) Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. BMC Research Notes, 9, 218.
  13. Goto S, Hida K, Furukawa TA & Sakai Y (2016) Subcuticular sutures for skin closure in non-obstetric surgery [Protool]. Cochrane Database of Systematic Reviews.
  14. Hoshino N, Hasegawa S, Takada T, Hida K, Furukawa TA & Sakai Y (2016) Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery [Protocol]. Cochrane Database of Systematic Reviews.
  15. Imai H, Tajika A, Chen P, Pompoli A & Furukawa TA (2016) Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. Cochrane Database of Systematic Reviews, 10, CD011170.
  16. Kanata S, Koike S, Ando S, Nishida A, Usami S, Yamasaki S, Morimoto Y, Toriyama R, Fujikawa S, Sugimoto N, Sasaki T, Furukawa TA, Hiraiwa-Hasegawa M & Kasai K (2016) Enuresis and Hyperactivity-Inattention in Early Adolescence: Findings from a Population-Based Survey in Tokyo (Tokyo Early Adolescence Survey). PLoS ONE, 11, e0158786.
  17. Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA & Salanti G (2016) Network meta-analyses should be the highest level of evidence in treatment guidelines. European Archives of Psychiatry and Clinical Neuroscience, 266, 477-480.
  18. Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Klevzon A & Leucht S (2016) Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. European Psychiatry, 32, 16
  19. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O & Salanti G (2016) Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 4, CD011004.
  20. Ogawa S, Kondo M, Ino K, Imai R, Ii T, Furukawa TA & Akechi T (2016) Anxiety sensitivity and comorbid psychiaric symptoms over the course of cognitive behavioural therapy for panic disorder. British Journal of Medicine and Medical Research, 13, 1-7.
  21. Ogawa S, Imai R, Kondo M, Furukawa TA & Akechi T (2016) Predictors of comorbid psychological symptoms among patients with social anxiety disorder after cognitive-behavioral therapy. Open Journal of Psychiatry, 6, 102-106.
  22. Onishi A & Furukawa TA (2016) State-of-the-Art Reporting. In Umbrella Reviews: Evidence Synthesis with Overviews of Reviews and Meta-Epidemiologic Studies. (ed Biondi-Zoccai G), pp. 189-202. Heidelberg, New York, Dordrecht, London: Springer International Publishing.
  23. Takagaki K, Okamoto Y, Jinnin R, Mori A, Nishiyama Y, Yamamura T, Yokoyama S, Shiota S, Okamoto Y, Miyake Y, Ogata A, Kunisato Y, Shimoda H, Kawakami N, Furukawa TA & Yamawaki S (2016) Behavioral activation for late adolescents with subthreshold depression: a randomized controlled trial. European Child and Adolescent Psychiatry, 25, 1171-1182.
  24. Takagaki K, Okamoto Y, Jinnin R, Mori A, Nishiyama Y, Yamamura T, Yokoyama S, Shiota S, Okamoto Y, MIyake Y, Ogata A, Shimoda H, Kawakami N, Furukawa TA & Yamawaki S (2016) Mechanisms of behavioral activation for late adolescent: Positive reinforcement mediate the relationship between activation and depressive symptoms from pre-treatment to post-treatment. Journal of Affective Disorders, 204, 70-73.
  25. Takekita Y, Suwa T, Sunada N, Kawashima H, Fabbri C, Kato M, Tajika A, Kinoshita T, Furukawa TA & Serretti A (2016) Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 266, 703-717.
  26. Takeshima N, Ogawa Y, Hayasaka Y & Furukawa TA (2016) Continuation and discontinuation of benzodiazepine prescriptions: A cohort study based on a large claims database in Japan. Psychiatry Research, 237, 201-207.
  27. Tomitaka S, Kawasaki Y, Ide K, Yamada H, Miyake H & Furukawa TA (2016) Distribution of Total Depressive Symptoms Scores and Each Depressive Symptom Item in a Sample of Japanese Employees. PLoS ONE, 11, e0147577.
  28. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H, Furukawa TA & Ono Y (2016) Boundary curves of individual items in the distribution of total depressive symptom scores approximate an exponential pattern in a general population. PeerJ, 4, e2566.
  29. Tomitaka S, Kawasaki Y, Ide K, Akutagawa M, Yamada H, Furukawa TA & Ono Y (2016) Relationship between Item Responses of Negative Affect Items and the Distribution of the Sum of the Item Scores in the General Population. PLoS ONE, 11, e0165928.
  30. Tomitaka S, Kawasaki Y, Ide K, Yamada H, Furukawa TA & Ono Y (2016) Age-related changes in the distributions of depressive symptom items in the general population: Cross-sectional study using the exponential distribution model. PeerJ, 4, e1547.
  31. Suganuma AM, Shinohara K, Imai H, Takeshima N, Hayasaka Y & Furukawa TA (2016) Overstatements in abstract conclusions claiming effectiveness of interventions in psychiatry: a study protocol for a meta-epidemiological investigation. BMJ Open, 6, e009832.
  32. Yamada A, Miyachi N, Miura T, Suzuki M, Watanabe N, Akechi T (2016) Long-term poor rapport, lack of spontaneity and passive social withdrawal related to acute post-infectious encephalitis: a case report. SpringerPlus, 5, 345.
  33. Yamasaki S, Ando S, Koike S, Usami S, Endo K, French P, Sasaki T, Furukawa TA, Hasegawa-Hiraiwa M, Kasai K & Nishida A (2016) Dissociation mediates the relationship between peer victimizatiion and hallucinatory experiences among early adolescents. Psychiatry Research: Cognition, 4, 18-23.
  34. Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, Furukawa TA, Baldessarini RJ, Lim BP & Sim K (2016) Long-term antipsychotic treatment in schizophrenia: Systematic review and network meta-analysis of randomised controlled trials. BJPsych Open, 2, 59-66.

2015

  1. Akechi T & Furukawa TA (2015) Depressed with cancer can respond to antidepressants, but further research is needed to confirm and expand on these findings. Evidence-Based Mental Health, 18, 28.
  2. Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, Hawton K & Cipriani A (2015) Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews, CD011612.
  3. Chaudhry H, Foote CJ, Guyatt G, Thabane L, Furukawa TA, Petrisor B & Bhandari M (2015) Network Meta-analysis: Users' Guide for Surgeons: Part II - Certainty. Clinical Orthopaedics and Related Research, 473, 2172-2178.
  4. Foote CJ, Chaudhry H, Bhandari M, Thabane L, Furukawa TA, Petrisor B & Guyatt G (2015) Network Meta-analysis: Users' Guide for Surgeons: Part I - Credibility. Clinical Orthopaedics and Related Research, 473, 2166-2171.
  5. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A & Leucht S (2015) Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry, 72, 14-21.
  6. Furukawa TA (2015) Evidence-based case conference (5) Helping people with schizophrenia to quit smoking. Evidence-Based Mental Health, 18, 14-15.
  7. Furukawa TA (2015) Evidence-based case conference (6) Which drug is the best bet when your bipolar patient gets depressed? Evidence-Based Mental Health, 18, 80-81.
  8. Furukawa TA (2015) Evidence-based case conference (7) What course are we to expect for a child with her first manic episode? Evidence-Based Mental Health, 18, 111-112.
  9. Furukawa TA (2015) The relationship between depression and violent crime [Invited commentary]. Lancet Psychiatry, 2, 193-194.
  10. Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S & Furukawa TA (2015) Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of Affective Disorders, 180, 179-184.
  11. Hayasaka Y, Furukawa TA, Sozu T, Imai H, Kawakami N & Horikoshi M (2015) Enthusiasm for homework and improvement in subthreshold depression during behavior therapy: Secondary analysis of data from a randomized controlled trial. BMC Psychiatry, 15, 302.
  12. Imai H, Furukawa TA, Okumiya K, Wada T, Fukutomi E, Sakamoto R, Fujisawa M, Ishimoto Y, Kimura Y, Chen WL, Tanaka M & Matsubayashi K (2015) Postcard intervention for depression in community-dwelling older adults: A randomised controlled trial. Psychiatry Research, 229, 545-550.
  13. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S & Kasai K (2015) Does Internet-based cognitive behavioral therapy (iCBT) prevent major depressive episode for workers? A 12-month follow-up of a randomized controlled trial. Psychological Medicine, 45, 1907-1917.
  14. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S & Kasai K (2015) Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. Journal of Occupational and Environmental Medicine, 57, 578-584.
  15. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S & Kasai K (2015) Effects of an internet-based cognitive behavioral therapy (iCBT) intervention on preventing major depressive episode among workers: A protocol for a randomized controlled trial. BMJ Open, 5, e007590.
  16. Johnston BC, Ebrahim S, Carrasco-Labra A, Furukawa TA, Patrick D, Crawford MW, Hemmelgarn BR, Schunemann HJ, Guyatt GH & Nesrallah G (2015) Minimally important difference estimates and methods: A protocol. BMJ Open, 5, e007953.
  17. Katsura M, Kuriyama A, Takeshima T, Fukuhara S & Furukawa TA (2015) Preoperative inspiratory muscle training for postoperative pulmonary complications in adult patients undergoing cardiac and major abdominal surgery. Cochrane Database of Systematic Reviews, CD010356.
  18. Kondo M, Kiyomizu K, Goto F, Kitahara T, Imai T, Hashimoto M, Shijogori H, Ikezono T, Nakayama J, Watanabe N, Akechi T (2015) Analysis of vestibular-balance symptoms according to sympotom duration: Dimensionality of the Vertigo Symptom Scale-short form. Health and Quality of Life Outcomes, 13, 4.
  19. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, Geddes J & Davis JM (2015) Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophrenia Bulletin, 41, 1397-1402.
  20. Onishi A, Iwasaku M, Sato A & Furukawa TA (2015) Interventions for the management of esophageal candidasis in immunocomopromised patients [Protocol]. Cochrane Database of Systematic Reviews, CD011938.
  21. Obbarius A, Clark D, Crocker AG, Emmelkamp P, Furukawa TA, Hedman E, Kangas M, Lesage A, Mwesigire DM, Nolte S, Patel V, Pilkonis P, Pincus HA, Reis RA, Rojas G, Sherbourne C, Stowell C & Rose M (2015) A proposal for standardization of health outcome measures for depression and anxiety. Quality of Life Research, 24, 110-111.
  22. Sakai K, Fujita K, Sozu T, Nakayama T & Furukawa TA (2015) Eradication of helicobacter pylori for iron metabolism [Protocol]. Cochrane Database of Systematic Reviews, CD011480.
  23. Sugihara G & Tajika A (2015) Can we predict switch from unipolar depression to bipolar disorder? [Letter]. British Journal of Psychiatry, 206, 79.
  24. Shinohara K, Tajika A, Imai H, Takeshima N, Hayasaka Y & Furukawa TA (2015) Protocol registration and selective outcome reporting in recent psychiatry trials: new antidepressants and cognitive behavioural therapies. Acta Psychiatrica Scandinavica, 132, 489-498.
  25. Tajika A, Ogawa Y, Takeshima N, Hayasaka Y & Furukawa TA (2015) Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. British Journal of Psychiatry, 207, 357-362.
  26. Tomitaka S, Kawasaki Y & Furukawa TA (2015) Right tail of the distribution of depressive symptoms is stable and follows an exponential curve during middle adulthood. PLoS ONE, 10, e0114624.
  27. Tomitaka S, Kawasaki Y & Furukawa TA (2015) A distribution model of the responses to each depressive symptoms item in a general population. Cross-sectional study. BMJ Open, 5, e008599.
  28. Watanabe K, Yokoyama K & Furukawa TA (2015) Reliability and validity of the Japanese version of the coping inventory for adults for stressful situations in healthy people. Psychological Reports, 116, 447-469.
  29. Watanabe N, Furukawa TA, Shimodera S, Katsuki F, Fujita H, Sasaki M, Sado M & Perlis ML (2015) Cost-effectiveness of cognitive behavioral therapy for insomnia comorbid with depression: Analysis of a randomized controlled trial. Psychiatry and Clinical Neurosciences, 69, 335-343.
  30. Watanabe N, Furukawa TA, Horikoshi M, Katsuki F, Narisawa T, Kumachi M, Oe Y, Shinmei I, Noguchi H, Hamazaki K & Matsuoka Y (2015) A mindfulness-based stress management program and treatment with omega-3 fatty acids to maintain a healthy mental state in hospital nurses - Happy Nurse Project: study protocol for a randomized controlled trial. Trials, 16, 36.
  31. Watanabe N, Horikoshi M, Yamada M, Shimodera S, Akechi T, Miki K, Inagaki M, Yonemoto N, Imai H, Tajika A, Ogawa Y, Takeshima N, Hayasaka Y & Furukawa TA (2015) Adding smartphone-based cognitive-behaviour therapy to pharmacotherapy for major depression (FLATT project): study protocol for a randomized controlled trial. Trials, 16, 293.
  32. Yonemoto N, Tanaka S, Furukawa TA, Kato T, Mantani A, Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Shinohara A, Miki K, Inagaki M, Shimodera S, Akechi T, Yamada M, Watanabe N & Guyatt GH (2015) Strategic Use of New generation antidepressants for Depression: SUN(^_^)D protocol update and statistical analysis plan. Trials, 16, 459.
  33. Zhang Y, Zhang S, Thabane L, Furukawa TA, Johnston BC & Guyatt GH (2015) Although not consistently superior, the absolute approach to framing the minimally important difference has advantages over the relative approach. Journal of Clinical Epidemiology, 68, 888-894.

2014

  1. Banno K, Nakaaki S, Sato J, Torii K, Oka M, Negi A, Narumoto J, Miyata J, Hirono N, Furukawa TA, Mimura M & Akechi T (2014) Neural basis of three dimensions of agitated behaviors in patients with Alzheimer disease. Neuropsychiatric Disease and Treatment, 10, 339-348.
  2. Chen P, Furukawa TA, Shinohara K, Honyashiki M, Imai H, Ichikawa K, Caldwell DM, Hunot V & Churchill R (2014) Quantity and quality of psychotherapy trials for depression in the past five decades. Journal of Affective Disorders, 165, 190-195.
  3. Cipriani A & Furukawa TA (2014) Advancing evidence-based practice to improve patient care. Evidence-Based Mental Health, 17, 1-2.
  4. Furukawa TA (2014) How can we make the results of trials and their meta-analyses using continuous outcomes clinically interpretable? Acta Psychiatrica Scandinavica, 130, 321-323.
  5. Furukawa TA & Guyatt G (2014) An illustration of bias and random error. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (3rd edn). (eds Guyatt G, Rennie D, Meade MO & Cook DJ), pp. 103-106. New York: The McGraw-Hill Companies, Inc.
  6. Furukawa TA, Scott I & Guyatt G (2014) Measuring patients' experience. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (3rd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 219-234. New York: The McGraw-Hill Companies, Inc.
  7. Furukawa TA, Strauss S, Bucher HC, Agoritsas T & Guyatt G (2014) Diagnostic tests. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice (3rd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 345-358. New York: The McGraw-Hill Companies, Inc.
  8. Furukawa TA (2014) Anxiety disorders in non-Western cultures. In The Whiley Handbook of Anxiety Disorders. (eds Emmelkamp P & Ehring T), pp. 612-621. Chichester, UK: John Wiley & Sons, Ltd.
  9. Furukawa TA (2014) Case study in psychiatry. In Network Meta-Analysis: Evidence Synthesis with Mixed Treatment Comparison. (ed Biondi-Zoccai G). Hauppauge, NY: Nova Science Publishers.
  10. Furukawa TA (2014) Evidence-Based Case Conference (1) Antidepressants during ECT. Evidence-Based Mental Health, 17, 25-26.
  11. Furukawa TA (2014) Evidence-Based Case Conference (2) Diagnostic test for dementias. Evidence-Based Mental Health, 17, 45-46.
  12. Furukawa TA (2014) Evidence-Based Case Conference (3) Prognosis of a brief psychotic episode. Evidence-Based Mental Health, 17, 81-82.
  13. Furukawa TA (2014) Evidence-Based Case Conference (4) Adverse effects of antidepressants during pregnancy. Evidence-Based Mental Health, 17, 103-104.
  14. Furukawa TA, Noma H, Caldwell DM, Honyashiki M, Shinohara K, Imai H, Chen P, Hunot V & Churchill R (2014) Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatrica Scandinavica, 130, 181-192.
  15. Furukawa TA, Watanabe N, Kinoshita Y, Kinoshita K, Sasaki T, Nishida A, Okazaki Y & Shimodera S (2014) Public speaking fears and their correlates among 17,615 Japanese adolescents. Asia-Pacific Psychiatry, 6, 99-104.
  16. Hashimoto N, Nakaaki S, Kawaguchi A, Sato J, Kasai H, Nakamae T, Narumoto J, Miyata J, Furukawa TA & Mimura M (2014) Brain structural abnormalities in behavior therapy-resistant obsessive-compulsive disorder revealed by voxel-based morphometry. Neuropsychiatric Disease and Treatment, 10, 1987-1996.
  17. Honda M, Kuriyama A & Furukawa TA (2014) Comments on "Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study". Gastric Cancer, 17, 757-758.
  18. Honda M, Kuriyama A, Noma H, Nunobe S & Furukawa TA (2014) Reply to Letter: "The Meta-analyses With Transparency Are Needed". Annals of Surgery.
  19. Honda M, Yamamoto K & Furukawa TA (2014) Retrospective propensity score matching and the selection of surgical procedures: how precise can a propensity estimate be? Journal of Clinical Oncology, 32, 3200-3201.
  20. Honyashiki M, Furukawa TA, Noma H, Tanaka S, Chen P, Ichikawa K, Ono M, Churchill R, Hunot V & Caldwell DM (2014) Specificity of CBT for depression: a contribution from multiple treatments meta-analyses. Cognitive Therapy and Research, 38, 249-260.
  21. Imai H, Furukawa TA, Kasahara Y, Ishimoto Y, Kimura Y, Fukutomi E, Chen WL, Tanaka M, Sakamoto R, Wada T, Fujisawa M, Okumiya K & Matsubayashi K (2014) The ipsative imputation for a 15-item Geriatric Depression Scale in community-dwelling elderly people. Psychogeriatrics, 14, 182-187.
  22. Imai H, Tajika A, Chen L, Pompoli A & Furukawa TA (2014) Psychological therapies versus pharmacological interventions for panic disorder [Protocol]. Cochrane Database of Systematic Reviews, CD011170.
  23. Imai H, Tajika A, Chen P, Pompoli A, Guaiana G, Castellazzi M, Bighelli I, Girlanda F, Barbui C, Koesters M, Cipriani A & Furukawa TA (2014) Azapirone versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews, CD010828.
  24. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S & Kasai K (2014) Effects of an internet-based cognitive behavioral therapy (iCBT) program in Manga format on improving subthreshold depressive symptoms among healthy workers: A randomized controlled trial. PLoS ONE, 9, e97167.
  25. Katsura M, Kuriyama A, Takeshima T, Fukuhara S & Furukawa TA (2014) Preoperative inspiratory muscle training for postoperative pulmonary complications in adult patients undergoing cardiac and major abdominal surgery [Protocol]. Cochrane Database of Systematic Reviews, CD010356.
  26. Kimachi M, Furukawa TA, Kimachi K, Goto Y & Fukuhara S (2014) New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease [Protocol]. Cochrane Database of Systematic Reviews, CD011373.
  27. Miura T, Furukawa TA, Cipriani A, Motomura K, Mitsuyasu H, Tanaka S, Leucht S, Shimano-Katsuki S, Salanti G, Noma H, Stockton S, Geddes JR & Kanba S (2014) Bipolar treatment efficacy - Author's replay. Lancet Psychiatry, 1, 418-419.
  28. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR & Kanba S (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A network meta-analysis. Lancet Psychiatry, 1, 351-359.
  29. Ogawa Y, Tajika A, Takeshima N, Hayasaka Y & Furukawa TA (2014) Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs, 28, 989-1003.
  30. Onishi A & Furukawa TA (2014) Publication bias is underreported in systematic reviews published in high-impact-factor journals: metaepidemiologic study. Journal of Clinical Epidemiology, 67, 1320-1326.
  31. Onishi A, Sato A, Iwasaku M & Furukawa TA (2014) Human parathyroid hormone for treating glucocorticoid-induced osteoporosis [Protocol]. Cochrane Database of Systematic Reviews, CD011299.
  32. Pompoli A, Furukawa TA, Imai H, Tajika A, Efthimiou O & Salanti G (2014) Psychological therapies for panic disorder with or without agoraphobia in adults [Protocol]. Cochrane Database of Systematic Reviews, CD011004.
  33. Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A & Barbui C (2014) Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews, CD006531.
  34. Shimodera S, Watanabe N, Furukawa TA, Katsuki F, Fujita H, Sasaki M & Perlis ML (2014) Change in quality of life afer brief behavioural therapy for insomnia in concurrent depression: Analysis of the effects of a randomized controlled trial. Journal of Clinical Sleep Medicine, 10, 433-439.
  35. Shiraishi N, Nishida A, Shimodera S, Sasaki T, Oshima N, Watanabe N, Akechi T, Furukawa TA & Okazaki Y (2014) Relationship between Violent Behavior and Repeated Weight-Loss Dieting among Female Adolescents in Japan. PLoS ONE, 9, e107744.
  36. Shiraishi N, Watanabe N, Kinoshita Y, Kaneko A, Yoshida S, Furukawa TA & Akechi T (2014) Brief psychoeducation for schizophrenia primarily intended to change the cognition of auditory hallucinations: an exploratory study. Journal of Nervous and Mental Disease, 202, 35-39.
  37. Suzuki M, Yamada A, Watanabe N, Akechi T, Katsuki F, Nishiyama T, Imaeda M, Miyachi T, Otaki K, Mitsuda Y, Ota A & Furukawa TA (2014) A failure to confirm the effectiveness of a brief group psychoeducational program for mothers of children with high-functioning pervasive developmental disorders: A randomized controlled pilot trial. Neuropsychiatric Disease and Treatment, 10, 1141-1153.
  38. Takeshima N, Furukawa TA, Hayasaka Y, Ogawa Y & Tajika A (2014) Ramelteon for primary insomnia [Protocol]. Cochrane Database of Systematic Reviews, CD011049.
  39. Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y & Furukawa TA (2014) Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Medical Research Methodology, 14, 30.
  40. Tomitaka S & Furukawa TA (2014) Mathematical model for the distribution of major depressive episode durations. BMC Research Notes, 7, 636.
  41. Yamamoto K, Honda M & Furukawa TA (2014) Video-assisted thoracoscopic surgery lobectomy or open lobectomy for non-small-cell lung cancer? Minimizing selection bias in observational studies. European Journal of Cardio-Thoracic Surgery, 46, 150.

Major publications before 2013

  • Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanicolas P, Akl EA, Vist G, Kunz R, Brozek J, Kupper LL, Martin SL, Meerpohl JJ, Alonso-Coello P, Christensen R & Schunemann HJ (2013) GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles-continuous outcomes. Journal of Clinical Epidemiology, 66, 173-183.
  • Furukawa TA, Horikoshi M, Kawakami N, Kadota M, Sasaki M, Sekiya Y, Hosogoshi H, Kashimura M, Asano K, Terashima H, Iwasa K, Nagasaku M, Grothaus LC & on behalf of the GENKI Project (2012) Telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace: a randomized controlled trial. PLoS ONE, 7, e35330.
  • Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N, Inagaki M & Yonemoto N (2011) Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials, 12, 116.
  • Furukawa TA, Akechi T, Wagenpfeil S & Leucht S (2011) Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research, 126, 212-219.
  • Furukawa TA & Leucht S (2011) How to obtain NNT from Cohen's d: comparison of two methods. PLoS ONE, 6, e19070.
  • Shimazu K, Shimodera S, Mino Y, Nishida A, Kamimura N, Sawada K, Fujita H, Furukawa TA & Inoue S (2011) Family psychoeducation for major depression: randomised controlled trial. British Journal of Psychiatry, 198, 385-390.
  • Watanabe N, Furukawa TA, Shimodera S, Morokuma I, Katsuki F, Fujita H, Sasaki M, Kawamura C & Perlis ML (2011) Brief behavioral therapy for refractory insomnia in residual depression: an assessor-blind, randomized controlled trial. The Journal of Clinical Psychiatry, 72, 1651-1658.
  • Kessler RC, Green JG, Gruber MJ, Sampson NA, Bromet E, Cuitan M, Furukawa TA, Gureje O, Hinkov H, Hu CY, Lara C, Lee S, Mneimneh Z, Myer L, Oakley-Browne M, Posada-Villa J, Sagar R, Viana MC & Zaslavsky AM (2010) Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative. International Journal of Methods in Psychiatric Research, 19 Suppl 1, 4-22.
  • Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., Tansella, M. & Barbui, C. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746-758.
  • Furukawa, T. A., Chen, J., Watanabe, N., Nakano, Y., Ietsugu, T., Ogawa, S., Funayama, T. & Noda, Y. (2009) Videotaped experiments to drop safety behaviors and self-focused attention for patients with social anxiety disorder: Do they change subjective and objective evaluations of anxiety and performance? Journal of Behavior Therapy and Experimental Psychiatry, 40, 202-210.
  • Furukawa, T. A., Yoshimura, R., Harai, H., Imaizumi, T., Takeuchi, H., Kitamura, T. & Takahashi, K. (2009) How many well vs. unwell days can you expect over 10 years, once you become depressed? Acta Psychiatrica Scandinavica, 119, 290-297.
  • Furukawa TA, Katherine Shear M, Barlow DH, Gorman JM, Woods SW, Money R, Etschel E, Engel RR & Leucht S (2009) Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. Depression and Anxiety, 26, 922-929.
  • Barbui C, Furukawa TA & Cipriani A (2008) Effectiveness of paroxetine in the acute phase treatment of adults with major depression: a systematic re-examination of published and unpublished randomised data. Canadian Medical Association Journal, 178, 296-305.
  • Furukawa TA, Fujita A, Harai H, Yoshimura R, Kitamura T & Takahashi K (2008) Definitions of recovery and outcomes of major depression: results from a 10-year follow-up. Acta Psychiatrica Scandinavica, 117, 35-40.
  • Furukawa TA, Kawakami N, Saitoh M, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Iwata N, Uda H, Nakane H, Watanabe M, Naganuma Y, Hata Y, Kobayashi M, Miyake Y, Takeshima T & Kikkawa T (2008) The performance of the Japanese version of the K6 and K10 in the World Mental Health Survey Japan. International Journal of Methods in Psychiatric Research, 17, 152-158.
  • Furukawa TA, Jaeschke R, Cook D & Guyatt G (2008) Measurement of patients' experience. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice (2nd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 249-271. New York: The McGraw-Hill Companies, Inc.
  • Furukawa TA, Strauss S, Bucher HC & Guyatt G (2008) Diagnostic tests. In Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice (2nd edn). (eds Guyatt G, Drummond R, Meade MO & Cook DJ), pp. 419-438. New York: The McGraw-Hill Companies, Inc.
  • Kinoshita Y, Chen J, Rapee RM, Bogels S, Schneier FR, Choy Y, Kwon JH, Liu X, Schramm E, Chavira DA, Nakano Y, Watanabe N, Ietzugu T, Ogawa S, Emmelkamp P, Zhang J, Kingdon D, Nagata T & Furukawa TA (2008) Cross-cultural study of conviction subtype Taijin Kyofu: proposal and reliability of Nagoya-Osaka diagnostic criteria for social anxiety disorder. Journal of Nervous and Mental Disease, 196, 307-313.
  • Furukawa TA, Watanabe N, Omori IM, Montori VM & Guyatt GH (2007) Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA, 297, 468-470.
  • Furukawa TA, Akechi T, Azuma H, Okuyama T & Higuchi T (2007) Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology, 27, 531-534.
  • Furukawa TA, Cipriani A, Barbui C & Geddes JR (2007) Long-term treatment of depression with antidepressants: A systematic narrative review. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 52, 545-552.
  • Tabuse H, Kalali A, Azuma H, Ozaki N, Iwata N, Naitoh H, Higuchi T, Kanba S, Shioe K, Akechi T & Furukawa TA (2007) The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training. Psychiatry Research, 153, 61-67.
  • Watanabe N, Hunot V, Omori IM, Churchill R & Furukawa TA (2007) Psychotherapy for depression among children and adolescents: a systematic review. Acta Psychiatrica Scandinavica, 116, 84-95
  • Akechi T, Okuyama T, Sugawara Y, Shima Y, Furukawa TA & Uchitomi Y (2006) Screening for depression in terminally ill cancer patients in Japan. Journal of Pain and Symptom Management, 31, 5-12.
  • Cipriani A, Barbui C, Brambilla P, Furukawa T, Hotopf M & Geddes J (2006) Are all antidepressants really the same? The case of fluoxetine: a systematic review. Journal of Clinical Psychiatry, 67, 850-864.
  • Furukawa TA, Watanabe N & Churchill R (2006) Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. British Journal of Psychiatry, 188, 305-312.
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P & Watanabe N (2006) Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology, 59, 7-10.
  • Furukawa TA & Guyatt GH (2006) Sources of bias in studies of diagnostic tests and the diagnostic process. Canadian Medical Association Journal, 174, 481-482.
  • Lee K, Noda Y, Nakano Y, Ogawa S, Kinoshita Y, Funayama T & Furukawa TA (2006) Interoceptive hypersensitivity and interoceptive exposure in patients with panic disorder: specificity and effectiveness. BMC Psychiatry, 6, 32.
  • Furukawa TA, Streiner DL, Azuma H, Higuchi T, Kamijima K, Kanba S, Ozaki N, Aoba A, Murasaki M & Miura S (2005) Cross-cultural equivalence in depression assessment: Japan-Europe-North American study. Acta Psychiatrica Scandinavica, 112, 279-285.
  • Furukawa TA, Cipriani A, Barbui C, Brambilla P & Watanabe N (2005) Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology, 20, 49-52.
  • Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, Watanabe N, Maeda T & Furukawa TA (2005) Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Research, 135, 229-235.
  • Kawakami N, Takeshima T, Ono Y, Uda H, Hata Y, Nakane Y, Nakane H, Iwata N, Furukawa TA & Kikkawa T (2005) Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002-2003. Psychiatry and Clinical Neurosciences, 59, 441-452.
  • Sakurai A, Nagata T, Harai H, Yamada H, Mohri I, Nakano Y, Noda Y, Ogawa S, Lee K & Furukawa TA (2005) Is "relationship fear" unique to Japan? Symptom factors and patient clusters of social anxiety disorder among the Japanese clinical population. Journal of Affective Disorders, 87, 131-137.
  • Furukawa T (2004) Meta-analyses and megatrials: neither is the infallible, universal standard. Evidence-Based Mental Health, 7, 34-35.
  • Furukawa TA (2004) All clinical trials must be reported in detail and made publicly available. BMJ (Clinical Research Ed.), 329, 626.
  • Nakano Y, Oshima M, Sugiura-Ogasawara M, Aoki K, Kitamura T & Furukawa TA (2004) Psychosocial predictors of successful delivery after unexplained recurrent spontaneous abortions: a cohort study. Acta Psychiatrica Scandinavica, 109, 440-446.
  • Yamamoto I, Nakano Y, Watanabe N, Noda Y, Furukawa TA, Kanai T, Takashio O, Koda R, Otsubo T & Kamijima K (2004) Cross-cultural evaluation of the Panic Disorder Severity Scale in Japan. Depression and Anxiety, 20, 17-22.
  • Furukawa TA, Kessler RC, Slade T & Andrews G (2003) The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychological Medicine, 33, 357-362.
  • Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E & Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 361, 653-661.
  • Kanai T, Takeuchi H, Furukawa TA, Yoshimura R, Imaizumi T, Kitamura T & Takahashi K (2003) Time to recurrence after recovery from major depressive episodes and its predictors. Psychological Medicine, 33, 839-845.
  • Furukawa TA, Guyatt GH & Griffith LE (2002) Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology, 31, 72-76.
  • Furukawa TA, McGuire H & Barbui C (2002) Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ (Clinical Research Ed.), 325, 991-995.
  • Furukawa TA, Andrews G & Goldberg DP (2002) Stratum-specific likelihood ratios of the general health questionnaire in the community: help-seeking and physical co-morbidity affect the test characteristics. Psychological Medicine, 32, 743-748.
  • Kojima M, Furukawa TA, Takahashi H, Kawai M, Nagaya T & Tokudome S (2002) Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Research, 110, 291-299.
  • Sugiura-Ogasawara M, Furukawa TA, Nakano Y, Hori S, Aoki K & Kitamura T (2002) Depression as a potential causal factor in subsequent miscarriage in recurrent spontaneous aborters. Human Reproduction, 17, 2580-2584.
  • Furukawa TA, Goldberg DP, Rabe-Hesketh S & Ustun TB (2001) Stratum-specific likelihood ratios of two versions of the general health questionnaire. Psychological Medicine, 31, 519-529.
  • Furukawa TA, Streiner DL, Young LT & Kinoshita Y (2001) Antidepressants plus benzodiazepine for major depression. Cochrane Database of Systematic Reviews, Art. No.: CD001026. DOI: 001010.001002/14651858.CD14001026.
  • Furukawa TA, Kitamura T & Takahashi K (2000) Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. British Journal of Psychiatry, 177, 331-335.
  • Furukawa TA, Kitamura T & Takahashi K (2000) Treatment received by depressed patients in Japan and its determinants: naturalistic observation from a multi-center collaborative follow-up study. Journal of Affective Disorders, 60, 173-179.
  • Furukawa TA, Streiner DL & Hori S (2000) Discrepancies among megatrials. Journal of Clinical Epidemiology, 53, 1193-1199.
  • Furukawa TA (1999) From effect size into number needed to treat. Lancet, 353, 1680.
  • Furukawa T & Goldberg DP (1999) Cultural invariance of likelihood ratios for the General Health Questionnaire. Lancet, 353, 561-562.
  • Furukawa T, Nakanishi M & Hamanaka T (1997) Typus melancholicus is not the premorbid personality trait of unipolar (endogenous) depression. Psychiatry and Clinical Neurosciences, 51, 197-202.
  • Furukawa T & Shibayama T (1997) Intra-individual versus extra-individual components of social support. Psychological Medicine, 27, 1183-1191.
  • Furukawa T, Awaji R, Nakazato H & Sumita Y (1995) Predictive validity of subtypes of chronic affective disorders derived by cluster analysis. Acta Psychiatrica Scandinavica, 91, 379-385.
  • Furukawa T, Takahashi K, Kitamura T, Okawa M, Miyaoka H, Hirai T, Ueda H, Sakamoto K, Miki K & Fujita K (1995) The Comprehensive Assessment List for Affective Disorders (COALA): a polydiagnostic, comprehensive, and serial semistructured interview system for affective and related disorders. Acta Psychiatrica Scandinavica. Supplementum, 387, 1-36.
  • Furukawa T, Nakazato H & Sumita Y (1993) Characteristics of chronic outpatients with unipolar depression. Acta Psychiatrica Scandinavica, 88, 273-277.
  • Furukawa T & Sumita Y (1992) A cluster-analytically derived subtyping of chronic affective disorders. Acta Psychiatrica Scandinavica, 85, 177-182.
Copyright© 2010-22 Health Promotion and Human Behavior, Kyoto University. All Rights Reserved.
 
Top of Page